Skip to main content
NCBI home page
Frontiers in Pharmacology logoLink to Frontiers in Pharmacology
. 2022 Apr 4;13:831099. doi: 10.3389/fphar.2022.831099

Contribution of MicroRNAs in Chemoresistance to Cisplatin in the Top Five Deadliest Cancer: An Updated Review

Pía Loren 1, Nicolás Saavedra 1, Kathleen Saavedra 1, Nadine De Godoy Torso 2, Marília Berlofa Visacri 2, Patricia Moriel 3, Luis A Salazar 1,*
PMCID: PMC9015654  PMID: 35444536

Abstract

Cisplatin (DDP) is a well-known anticancer drug used for the treatment of numerous human cancers in solid organs, including bladder, breast, cervical, head and neck squamous cell, ovarian, among others. Its most important mode of action is the DNA-platinum adducts formation, inducing DNA damage response, silencing or activating several genes to induce apoptosis; these mechanisms result in genetics and epigenetics modifications. The ability of DDP to induce tumor cell death is often challenged by the presence of anti-apoptotic regulators, leading to chemoresistance, wherein many patients who have or will develop DDP-resistance. Cancer cells resist the apoptotic effect of chemotherapy, being a problem that severely restricts the successful results of treatment for many human cancers. In the last 30 years, researchers have discovered there are several types of RNAs, and among the most important are non-coding RNAs (ncRNAs), a class of RNAs that are not involved in protein production, but they are implicated in gene expression regulation, and representing the 98% of the human genome non-translated. Some ncRNAs of great interest are long ncRNAs, circular RNAs, and microRNAs (miRs). Accumulating studies reveal that aberrant miRs expression can affect the development of chemotherapy drug resistance, by modulating the expression of relevant target proteins. Thus, identifying molecular mechanisms underlying chemoresistance development is fundamental for setting strategies to improve the prognosis of patients with different types of cancer. Therefore, this review aimed to identify and summarize miRs that modulate chemoresistance in DDP-resistant in the top five deadliest cancer, both in vitro and in vivo human models.

Keywords: microRNA, drug-resistance, cisplatin, sensitivity, cancer

1 Introduction

Globally, cancer is the first leading cause of death. In 2020, 19.3 million new cases of cancer and almost 10 million deaths from cancer (Ferlay et al., 2021; Sung et al., 2021). Cisplatin [cis-diamminedichloroplatinum (II), DDP], discovered by Rosenberg and his colleagues in 1965 (Rosenberg et al., 1969), was the first platinum compound approved by FDA for cancer treatment in the United States in 1978 (FDA, 1978). It is a well-known chemotherapeutic drug used for the treatment of numerous human cancer in solid organs, including head and neck, testis, small cells and non-small cells lung cancer, ovarian, cervical, and bladder. Once DDP crosses the cytosol, the low concentration of chloride present triggers two hydrolyses of the DDP, forming positively charged DDP derivative, which binds to negatively charged DNA bases, inducing DNA damage by forming DNA-platinum adducts, and simultaneously initiating self-defense mechanisms to activate or silence multiple genes, resulting in DNA damage response and repair pathways (Hu et al., 2016), cell cycle arrest (Velma et al., 2016) and DDP-induced apoptosis (Tanida et al., 2012). However, treatment response to DDP differs, and the main problem to its effectiveness is the development of drug resistance (Amable, 2016; Ko and Li, 2019). Cisplatin-resistance is inferred mainly when the usual clinical dose of DDP is magnified in drug-intensive therapy protocols and may require cytotoxic concentrations as much as 50–100-fold in addition to those needed for sensitive cells (Siddik, 1999). In fact, any factor that influences those processes can lead to the development of resistance to DDP. Moreover, drug resistance is responsible for over 90% of deaths in cancer patients receiving traditional chemotherapeutic drugs (Bukowski et al., 2020). Besides, the epithelial-mesenchymal transition (EMT) process contributes to chemoresistance by transforming epithelial cells into mesenchymal cells and altering cell-cell adhesion as well as the cellular extracellular matrix, leading to invasion of tumor cells (Ashrafizadeh et al., 2020). Autophagy, a process which degrades and recycles cellular proteins and organelles in response to cellular stresses, has been shown to attenuate the sensitivity of therapeutic drugs, protecting cancerous cells from death (Li W. et al., 2019). Thus, there is a crucial necessity to comprehend the underlying molecular mechanisms and recognize strategies to counteract DDP and facilitate predictions of the clinical response to therapy.

Non-coding RNAs are molecules that regulate gene expression under physiological and pathological conditions (Virginie et al., 2019) and are further divided into two principal groups, small ncRNAs (shorter than 200 bp) and long ncRNA (longer than 200 bp). MicroRNAs a class of small ncRNAs, are a kind of short-chain, linear, approximately 21–25 nucleotides long that negatively regulate gene targets the post-transcriptional level by perfect complementarity of their “seed” region to 3′-UTR of its target mRNA, inducing their degradation. If there is a mismatch or imperfect complementarity, it results in translational repression (Guo et al., 2019). The latest release of the miRbase database (v22) contains 2654 human mature miRs sequences (Kozomara et al., 2019), which confirms their importance on gene expression regulation. Not surprisingly, atypical expression and/or activity of ncRNAs can affect the outcome of cancer treatment and allow tumors to acquire drug-resistant phenotypes (Yo et al., 2012; Tang et al., 2020). An increasing number of studies have shown that ncRNAs play an essential role in several types of cancer and miRs have been associated with DDP resistance, making them important potential therapeutic targets. So, in this narrative review, we summarize the current literature on the contribution of miRs that modulate chemoresistance to DDP in the top five deadliest cancer reported in 2020, some strategies to sensitize DDP-cells and reduce their malignant capacities, both in vitro and in vivo human models.

2 The Top Five Deadliest Cancer

The most common cause of cancer death for about 13% of total cancer diagnoses remains by far lung cancer (Ferlay et al., 2021; Sung et al., 2021). The global incidence of lung cancer estimated in 2020 was approximately 2206800 new cases and 1796100 cancer deaths (Figure 1). In terms of clinical and tumor genetics, lung cancer can be divided into small and non-small cell lung cancer. Non-small cell lung cancer (NSCLC) represents about 80%–95% of all diagnosed lung cancer cases, and NSCLC remains the leading cause of cancer death worldwide. The efficacy of DDP-based chemotherapy in cancer is limited by the occurrence of innate and acquired drug resistance and acquired resistance of NSCLC cells against cisplatin is the consequence of altered signaling leading to reduced G2/M cell cycle arrest and apoptosis (Sarin et al., 2017). On the other hand, small-cell lung cancer (SCLC) is a distinct form of lung cancer with unique clinical and histological characteristics, representing 10%–15% of all new cases of lung cancer, and SCLC cancer tends to grow and spread faster than NSCLC (Kitamura et al., 2009). SCLC is highly sensitive to the initial cycle of chemotherapy and, in many cases chemotherapy-resistant SCLC emerges, leading to rapid patient mortality. DDP-resistance in lung cancer can be induced by alterations to a huge number of intracellular pathways, where miRNAs play a vital role (Table 1), even though very few studies have demonstrated the role of miR on DDP-resistance in SCLC.

FIGURE 1.

FIGURE 1

Open in a new tab

Estimated number of new cancer cases and cancer deaths worldwide for 2020 (Ferlay et al., 2021; Sung et al., 2021).

TABLE 1.

MicroRNAs involved in DDP-chemoresistance in lung cancer.

miR Target Model Expression References
miR-1 ATG3 in vitro: A-549 & NCI-H1299 cells Down Hua et al. (2018)
in vivo: 30 DDP-resistant non-small cell lung cancer patient samples
miR-7 Bcl-2 in vitro: SPC-A1 cells Down Cheng et al. (2017)
in vivo: 108 paired of resected tumors from lung adenocarcinoma patients
miR-10a PIK3CA in vitro: A-549 & NCI-H1299 cells Up Huang T. et al. (2020)
in vivo: Blood samples from 6 lung adenocarcinoma patients
STAT3, STAT5 in vitro: A-549/DDP cells Up Sun et al. (2015)
miR-15b PEBP4 in vitro: A-549/DDP cells Up Zhao et al. (2015)
in vivo: 30 tissues collected from patients with advanced lung adenocarcinoma
miR-17 ATG7 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Huang FX et al. (2019)
miR-18a IRF-2 in vitro: NCI-H226/DDP & A-549/DDP cells Up Xiao and He, (2020)
in vivo: Lung biopsies of 85 non-small cell lung cancer patients
PTEN in vitro: A-549/DDP Up Xiao et al. (2018)
in vivo: 40 non-small cell lung cancer tissue samples
miR-19a PTEN in vitro: A-549/DDP & NCI-H460/DDP cells Up Xiao et al. (2020)
in vitro: 68 subjects diagnosed with non-small cell lung cancer
miR-21 PTEN in vitro: A-549/DDP cells Up Liang et al. (2021)
miR-25 Cyclin E2 in vitro: NCI-H146, NCI-H209, NCI-H446, NCI-H510A & NCI-H889 cells Up Zhao et al. (2014)
in vivo: 9 pairs of small cell lung cancer tumor tissues
miR-25-3p PTEN in vitro: A-549/DDP & NCI-H1299/DDP cells Up Sun et al. (2021a)
miR-26a HMGA2 in vitro: A-549/DDP cells Down Yang et al. (2016)
miR-29a REV3L in vitro: A-549/DDP cells Down Chen et al. (2019b)
in vivo: 30 non-small cell lung cancer tissues obtained from 30 patients
miR-29b-3p COL1A1 in vitro: A-549/DDP cells Down Jia and Wang, (2020)
in vivo: 20 cases of tumor tissues
miR-31 ABCB9 in vitro: SPC-A1, LTEP-a2, NCI-H460 & NCI-H1299 cells Up Dong et al. (2014)
miR-32 ROBO1 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Zheng et al. (2021b)
in vivo: Non-small cell lung cancer patient samples
miR-34a-5p TRIM29 in vitro: HCC827, NCI-H522 & NCI-H23 cells Down Luo et al. (2020)
in vivo: 50 lung cancer specimens
miR-96 LMO7 in vitro: A-549, PC-9 & NCI-H1299 cells Up Wu et al. (2017)
in vivo: 56 lung adenocarcinoma patient specimens
miR-98-5p CTR1 in vitro: A-549/DDP cells Up Jiang et al. (2016)
miR-100-5p mTOR in vitro: A-549/DDP cells Down Qin et al. (2017)
miR-101-3p MCL-1 in vitro: A-549 and NCI-H1299 cells Down Wang et al. (2018)
Not reported in vitro: NCI-H460, A-549 & SK-MES-1 cells Down Hua et al. (2021)
in vivo: Samples of 25 lung cancer patients
miR-103a-3p NF-1 in vitro: A-549/DDP cells Up Zhu et al. (2020a)
in vivo: 20 patients with non-small cell lung cancer
miR-106a ABCA1 in vitro: A-549/DDP cells Up Ma et al. (2015)
miR-106b-5p PKD2 in vitro: A-549/DDP cells Down Yu et al. (2017)
miR-127-3p MDM2 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Zeng et al. (2020)
in vivo: 40 non-small cell lung cancer patients who receiver surgical resection
miR-128-2 E2F5 in vitro: A-549 cells Up Donzelli et al. (2012)
miR-130b PTEN in vitro: A-549/DDP & NCI-H446/DDP cells Up Zhang et al. (2018)
miR-133b GSTP1 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Lin et al. (2018)
miR-134 FOXM1 in vitro: A-549/DDP cells Down Li et al. (2017)
miR-138-5p ATG7 in vitro: A-549/DDP cells Down Pan et al. (2019)
in vivo: Samples of 60 non-small cell lung cancer subjects
miR-140-3p Wnt/β-catenin in vitro: A-549, NCI-H1299, NCI-H292 & Calu-3 cells Down Wu et al. (2020b)
in vivo: RNA array dataset GSE74190
miR-142-5p PD-L1 in vitro: A-549/DDP & HCC827/DDP cells Down Zhu et al. (2021)
in vivo: Samples of 46 lung adenocarcinoma patients
miR-144-3p Not reported in vitro: A-549C/DDP & NCI-H460/DDP cells Down Tian et al. (2019)
in vivo: 54 tissue samples from patients with non-small cell lung cancer
miR-145 CDK6 in vitro: Calu-6 & Calu-6/DDP cells Up Bar et al. (2015)
in vivo: Primary tumors of patients with non-small cell lung cancer
KLF4 in vitro: A-549/DDP cells Down Cui et al. (2018)
in vivo: 52 tumor tissue samples from patients with non-small cell lung cancer
Not reported in vitro: A-549/DDP cells Down Zhang et al. (2019)
miR-146a JNK-2 in vitro: A-549/DDP cells Down Pang et al. (2017)
NF-κB1 in vitro: A-549/DDP & Calu-1/DDP Down Jiang et al. (2017a)
in vivo: 28 non-small cell lung cancer tissues from patients
miR-148b DNMT1 in vitro: A-549/DDP & SPC-A1/DDP cells Down Sui et al. (2015)
miR-149-5p DCLK1 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Zhan et al. (2020)
in vivo: 70 samples of patients with non-small cell lung cancer
miR-152 Bcl-2, NF-κB in vitro: A-549 & A-549/DDP cells Down Zhao et al. (2019)
miR-182-5p GLI2 in vitro: NCI-H460/DDP & A-549/DDP cells Down Seidl et al. (2020)
in vivo: 27 lung adenocarcinoma tissue
miR-185-5p ABCC1 in vitro: A-549/DDP cells Down Pei et al. (2016)
miR-186-5p SIX1 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Liu et al. (2020b)
in vivo: Samples of 50 non-small cell lung cancer patients
miR-195-5p CHEK1 in vitro: A-549 & NCI-H1299 cells Down Zuo et al. (2019)
miR-196a Not reported in vitro: A-549/DDP cells Up Li et al. (2016a)
miR-200a β-catenin in vitro: A-549/DDP cells Down Tang et al. (2020)
miR-200b Bcl-2, XIAP in vitro: A-549/DDP cells Down Sun et al. (2012)
miR-200c Bcl-2, XIAP in vitro: A-549/DDP cells Down Zhu et al. (2012a)
No Reported in vitro: Calu-1, NCI-H520, SK-MES-1, H596, Calu-3, NCI-H522, NCI-H1395, NCI-H1299 & NCI-H460 cells lines Down Ceppi et al. (2010)
in vivo: Non-small cell lung cancer patient samples
miR-200c-3p ERCC3, ERCC4 in vitro: SGC-7901/DDP cells Down Li et al. (2019a)
miR-202 KRAS in vitro: NCI-H441 & A-549 cells Down Sun et al. (2018)
in vivo: 25 primary non-small cell lung cancer tumor tissues
miR-202-5p P-gp in vitro: A-549/DDP cells Down Shen et al. (2020a)
miR-206 MET in vitro: A-549/DDP & NCI-H1299/DDP cells Down Chen et al. (2016b)
in vivo: 34 lung adenocarcinoma tissues
miR-216b Beclin-1 in vitro: A-549/DDP cells Down Chen et al. (2019a)
miR-217 LHPP in vitro: A-549/DDP cells Up Yang et al. (2021)
miR-219a-5p FGF9 in vitro: A-549/DDP & SPC-A1/DDP cells Down Rao et al. (2019)
in vivo: Tumor tissues collected from 81 non-small cell lung cancer patients
miR-223 FBXW7 in vitro: A-549, NCI-H358 & NCI-H1299 cells Up Wang et al. (2020b)
miR-326 WNT2B in vitro: NCI-H358, A-549, NCI-H1299 & NCI-H1650 cells Down Wu et al. (2020c)
in vivo: 180 tumors from patients with non-small cell lung cancer
miR-330-5p DCLK1 in vitro: A-549 & NCI-H1299/DDP cells Down Ge et al. (2021)
in vivo: DDP-resistant non-small cell lung cancer tissues
miR-377-3p GOT1 in vitro: A-549/DDP, NCI-H1299/DDP & Calu-3/DDP cells Down Zhu et al. (2020b)
miR-381 ID-1 in vitro: A-549, A-549/DDP & NCI-H460 cells Down Huang et al. (2018)
miR-383 RBM24 in vitro: A-549/DDP cells Down He et al. (2021)
in vivo: 93 Lung adenocarcinoma tissues
miR-429 Bcl-2, XIAP in vitro: A-549/DDP cells Down Zhu et al. (2012a)
miR-432 E2F3, AXL in vitro: A-549 & NCI-H1299 cells Down Chen et al. (2016a)
in vivo: human lung adenocarcinoma samples
miR-448 SATB1 in vitro: A-549/DDP cells Down Ning et al. (2020)
in vivo: 146 patients diagnosed with lung cancer
miR-451 Not reported in vitro: A-549 cells Down Bian et al. (2011)
in vivo: Non-small cell lung cancer patient samples
TRIM66 in vitro: A-549/DDP & H157/DDP cells Down Wang et al. (2019a)
in vivo: 30 non-small cell lung cancer tumor tissues
miR-454-3p STAT3 in vitro: A-549/DDP & H157/DDP cells Down Zhao et al. (2018)
miR-486-5p TWF1 in vitro: A-549/DDP cells Down Jin et al. (2019)
in vivo: 46 patient samples with non-small cell lung cancer
miR-493 TCRP1 in vitro: A-549/DDP cells Down Gu et al. (2017)
in vivo: Non-small cell lung cancer patient samples
miR-497 Bcl-2 in vitro: A-549/DDP cells Down Zhu et al. (2012b)
miR-503 FANCA in vitro: A-549, NCI-H446, NCI-H1650 & NCI-H1299 cells Down Li et al. (2014)
in vivo: 65 samples of non-small cell lung cancer patients
miR-514a-3p ULK1 in vitro: A-549/DDP cells Down Shen et al. (2020b)
in vivo: 30 DDP-resistant & 30 DDP-sensitive non-small cell lung cancer tissues
miR-519 ZBTB5 in vitro: SK-MES-1, NCI-H1299/DDP and A-549/DDP cells Down Tang et al. (2019)
in vivo: 40 lung cancer tissue samples
miR-548a ROBO1 in vitro: A-549/DDP & NCI-H1299/DDP cells Down Zheng et al. (2021b)
in vivo: Non-small cell lung cancer patient samples
miR-556-5p NLRP3 in vitro: A-549/DDP & NCI-H1299/DDP cells Up Shi et al. (2021)
in vivo: 47 non-small cell lung cancer patients
miR-630 Bcl-2 in vitro: NCI-H358, NCI-H23, A-549, NCI-H1299, TL-4 & CL1-0 cells Down Chen et al. (2018)
in vivo: 114 patients with non-small cell lung cancer
miR-641 HOXA9 in vitro: A-549/DDP, NCI-H1299/DDP & Calu-6/DDP cells Down Zhao et al. (2020b)
miR-1236-3p ATG7 in vitro: NCI-H522/DDP & A-549/DDP cells Down Wang et al. (2020c)
in vivo: 31 lung cancer tissues
miR-1244 TP53 in vitro: A-549/DDP cells Down Li et al. (2016b)
miR-1269b PTEN in vitro: A-549/DDP cells Up Yang et al. (2020a)
in vivo: 32 lung tissue samples obtained from non-small cell lung cancer patients
miR-4443 METTL3 in vitro: A-549/DDP &NCI-H460 cells Up Song et al. (2021)
in vivo: Non-small cell lung cancer tumor tissue
miR-4458 REV3L in vitro: A-549/DDP & NCI-H460/DDP cells Down Pang et al. (2020)
in vivo: 30 pairs of sensitive tissues and resistant samples
miR-4701-5p NFE2L1 in vitro: PC-9, Calu-3, A-549 & HCC827 cells Down Wei et al. (2020)
in vivo: 40 lung adenocarcinoma tissues
let-7i BAG-1 in vitro: A-549/DDP cells42 Down Sun et al. (2017)
in vivo: Lung adenocarcinoma tissue samples
Open in a new tab

Followed by lung cancer, the second cause of cancer death is due to liver cancer (Ferlay et al., 2021; Sung et al., 2021). Liver cancer comprises a heterogeneous group of malignant liver tumors with different histological features and an unfavorable prognosis (Anwanwan et al., 2020). The global incidence of liver cancer estimated in 2020 was approximately 905700 new cases and 830200 cancer deaths (Figure 1). The prognosis for liver cancer is poor, due to merely 5%–15% of patients are eligible for surgical removal, because of diminished hepatic regenerative capacity (Anwanwan et al., 2020). Treatment options for more advanced stages include chemotherapy, however, fewer than one-third of patients benefit from the treatment, and drug resistance is evident within 6 months of initiating the regimen (El-Serag et al., 2008). On this basis, miRs have been involved in DDP-resistance in lung cancer and will be listed in Table 2.

TABLE 2.

MicroRNAs involved in DDP-chemoresistance of liver cancer.

miR Target Model Expression References
miR-9-5p EIF5A2 in vitro: Hep 3B2.1-7, Hep-G2, SNU-387 & SNU-449 cells Down Bao et al. (2020)
miR-29c SIRT1 in vitro: Hep-G2/DDP cells Down Zhang and Luo, (2018)
miR-30a Beclin-1 in vitro: Hep-G2 cells Down Zou et al. (2012)
miR-31-5p MAGEA3 in vitro: Hep-G2 & Huh-7 cells Down Chen et al. (2020)
miR-33a-5p Not reported in vitro: Hep 3B2.1-7/DDP & MHCC97-L/DDP Down Meng et al. (2017)
miR-103 NOR1 in vitro: Hep3B2.1-7/DDP& Huh-7/DDP cells Up Luo et al. (2019)
in vivo: 120 hepatocellular carcinoma tissues
miR-155-5p PDK1 in vitro: Hep3 B2.1-7/DDP & Huh-7/DDP Down Li et al. (2021c)
in vivo: Samples of 82 hepatocellular carcinoma tumor tissue
miR-340-5p NRF2 in vitro: SMMC-7721/DDP, HuH7/DDP and Hep-G2/DDP cells Down Wu et al. (2019)
in vivo: 30 hepatocellular carcinoma tissues
miR-326 RUNX2 in vitro: Hep-G2 & Huh-7 cells Down Guan et al. (2020)
in vivo: Hepatocellular carcinoma patient samples
Open in a new tab

Followed by liver cancer, the third cause of cancer death is due to stomach cancer (Ferlay et al., 2021; Sung et al., 2021). Gastric cancer is one of the most commonly diagnosed malignancies. The global incidence of stomach cancer estimated in 2020 was approximately 1089100 new cases and 768800 cancer deaths (Figure 1). In recent years, a rising body of evidence has revealed that miRs are dysregulated in almost all types of tumors, including gastric, modulating the proliferation, stemness, tumor immune escape, invasion, angiogenesis, and drug resistance of tumor cells (Chen et al., 2021). Some studies in which miRs play a major role in mediating DDP-resistance in stomach cancer will be detailed in Table 3.

TABLE 3.

MicroRNAs involved in DDP-chemoresistance of stomach cancer.

miR Target Model Expression References
miR-21 PI3K, Akt, mTOR in vitro: AGS/DDP cells Up Gu et al. (2020)
PI3K/Akt in vitro: MGC-803 cells Up Zheng et al. (2017)
Not reported in vivo: 67 samples of gastric cancer patients Up Qi et al. (2017)
PTEN in vitro: SGC-7901/DDP cells Up Yang et al. (2013)
miR-25 FOXO3a in vitro: SGC-7901/DDP cells Up He et al. (2017)
miR-30a LC3-I, LC3-II in vitro: SGC-7901 & SGC-7901/DDP cells Down Du et al. (2018)
miR-34a ABCB1, ABCC1, ABCG2 in vitro: SGC-7901/DDP & MGC-803/DDP cells Down Cheng et al. (2018)
miR-34c E2F1 in vitro: SGC-7901 cells Down Zheng et al. (2020)
in vivo: 74 cases of paired gastric cancer tissues
miR-95-3p EMP1 in vitro: SGC-7901/DDP & AGS/DDP cells Up Ni et al. (2021)
in vivo: Biopsies of 32 advanced gastric cancer patients
miR-99a-5p MTMR3 in vitro: BGC-823/DDP & SGC-7901/DDP cells Down Sun et al. (2020a)
in vivo: 60 gastric cancer tissues
miR-106a PTEN, PI3K/Akt in vitro: SGC-7901 & SGC-7901/DDP cells Up Fang et al. (2013)
miR-122 ERCC1 in vitro: MKN74 cells Down Song et al. (2019)
in vivo: 60 samples collected from 60 gastric cancer patient
miR-126 VEGFA, PIK3R2 in vitro: SGC-7901/DDP & BGC-823/DDP cells Down Yan et al. (2016)
in vivo: 30 primary gastric cancer
miR-129 P-gp in vitro: BGC-823/DDP & MKN45/DDP cells Down Lu et al. (2017)
in vivo: 25 gastric cancer tissues
miR-138 FOXC1 in vitro: NCI-N87/DDP & AGS/DDP cells Down Sun et al. (2021b)
miR-138-5p ERCC1, ERCC4 in vitro: SGC-7901/DDP cells Down Ning et al. (2019)
miR-142-3p ROCK2 in vitro: AGS, SGC-7901, MKN45 & BGC-823 cells Up Peng et al. (2020)
in vivo: 100 gastric cancer tissues from patients
miR-144-3p UBE2D1 in vitro: AGS/DDP & MKN45/DDP cells Down Li et al. (2021b)
in vivo: Samples of 51 gastric cancer patients
miR-182-5p Not reported in vitro: SGC-7901/DDP & BGC-823/DDP cells Down Huang XX. et al. (2020)
in vivo: Tissues of 105 gastric cancer patients
miR-187 TGF-β/p-SMAD4 in vitro: SGC-7901/DDP cells Down Zhu et al. (2019)
miR-192-5p ERCC3, ERCC4 in vitro: SGC-7901/DDP cells Down Xie et al. (2019)
miR-198 PIK3R1 in vitro: SGC-7901/DDP & BGC-823/DDP Down Huang Z. et al. (2019)
in vivo: 149 gastric cancer tissues
miR-200c ZEB2 in vitro: SGC-7901/DDP cells Down Jiang et al. (2017b)
in vivo: 50 gastric cancer tissues
miR-216a-5p Bcl-2 in vitro: SGC-7901/DDP cells Down Zhao et al. (2020a)
in vivo: Tissues from 106 patients with stage II/III gastric cancer
miR-299-3p EndoPDI in vitro: AGS/DDP & HGC-27/DDP cells Down Yang et al. (2020b)
in vivo: DDP-resistant and DDP-sensitive gastric cancer tissues from 35 patients
miR-325-3p GITR in vitro: MKN45 & AGS cells Down Sun et al. (2020b)
in vivo: 137 tissues from gastric cancer patients
miR-362 CYLD, NF-κB in vitro: SGC-7901, BGC-823, HGC-27, MKN28 & MGC-803 cells Up Xia et al. (2014)
in vivo: 10 freshly collected gastric cancer tissues
miR-362-5p SUZ12 in vitro: SGC-7901/DDP cells Down Wei et al. (2019)
miR-363 FBW7 in vitro: MGC-803 & HGC-27 cells Up Zhang et al. (2016)
in vivo: 71 gastric cancer samples
miR-372 FOXO3a in vitro: MGC-803/DDP & MKN28/DDP cells Up Wang et al. (2020a)
miR-421 E-cadherin, caspase-3 in vitro: AGS, MKN28, MKN45, NCI-N87, HGC-27, SNU-16 & SGC-7901 cells Up Ge et al. (2016)
in vivo: 107 specimens of primary gastric adenocarcioma
miR-490-3p HMGA2 in vitro: BGC-823/DDP & SGC-7901/DDP cells Down Xia et al. (2021)
in vivo: Primary gastric cancer samples obtained from 100 patients
miR-497-5p ATG14 in vitro: BGC-823/DDP & SGC-7901/DDP Down Song et al. (2020)
in vivo: 30 gastric cancer patients
miR-503 E2F2 in vitro: SGC-7901, MKN45, BGC-823, HGC-27, MFC & SGC-7910/DDP Down Jiang et al. (2020)
miR-505 CYLD in vitro: BG-C823/DDP & SGC-7901/DDP cells Up Wang et al. (2020d)
miR-513a-3p CYP1B1 in vitro: AGS & NCI-N87 cells Down Cheng et al. (2021)
in vivo: 53 gastric cancer tumor tissues
miR-574-3p ZEB1 in vitro: SGC-7901/DDP cells Down Wang et al. (2019b)
miR-618 Bcl-2 in vitro: BGC-823/DDP & SGC-7901/DDP cells Down Zhang et al. (2020a)
in vivo: 92 gastric cancer tissues
miR-876-3p TMED3 in vitro: SGC-7901/DDP & MKN45/DDP cells Down Peng et al. (2019)
in vivo: Gastric cancer tissue samples collected from 50 patients
miR-3619-5p TBL1XR1 in vitro: AGS/DDP & NUGC-3/DDP cells Down Wu et al. (2020a)
in vivo: Gastric cancer tissues from DDP-resistant and DDP-sensitive patients
Open in a new tab

After stomach cancer, the fourth cause of cancer mortality is due to breast cancer (Ferlay et al., 2021; Sung et al., 2021). Breast cancer is the most commonly diagnosed cancer worldwide and female breast cancer is the most commonly diagnosed cancer (Sung et al., 2021). The global incidence estimated in 2020 was approximately 2261400 new cases and 685000 cancer deaths due to breast cancer (Figure 1). Cisplatin is currently the most effective drug used to treat breast cancer; however, DDP-resistance presents a major challenge in the successful treatment of breast cancer. Breast cancer can be invasive or non-invasive. Invasive breast cancer is cancer that spreads into adjacent tissues and/or distant organs, while non-invasive breast cancer does not go beyond the milk ducts or lobules in the breast (Beikman et al., 2013). Some studies in which miRs play a major role in mediating DDP-resistance in breast cancer will be detailed on Table 4.

TABLE 4.

MicroRNAs involved in DDP-chemoresistance of breast cancer.

miR Target Model Expression References
miR-133a FTL in vitro: MCF-7/DDP cells Down Chekhun et al. (2013)
miR-141-3p KLF12 in vitro: MCF-7 & MDA-MB-231 cells Up Zhou et al. (2021)
in vivo: 62 patients with breast cancer diagnosed
miR-199b-5p PXN in vitro: MDA-MB-231, Hs 578T, HCC 1806, HCC1599 & CAL-51 cells Down Du et al. (2020)
miR-203 SOCS3 in vitro: MCF-7, ZR-75 & MDA-MB-231 cells Up Ru et al. (2011)
in vivo: 10 specimens from breast cancer patients
miR-218 BRCA1 in vitro: MCF-7 & MCF-7/DDP cells Down He et al. (2015)
in vivo: BRC patient samples
miR-381 MDR1 in vitro: MCF-7/DDP & MDA-MB-231/DDP cells Down Yi et al. (2019)
in vivo: 46 tumor tissue specimens
Not reported in vitro: MCF-7/DDP & MDA-MB-231/DDP cells Down Mi et al. (2020)
in vivo: 42 tumor tissues obtained from breast cancer patients
miR-1307 MDM4 in vitro: MCF-7/DDP and MDA-MB-468/DDP cells Down Wang and Zhu, (2018)
Open in a new tab

The last cause of cancer mortality is due to colorectal cancer. Colorectal cancer starts when normal cells in the lining of the colon or rectum change and grow out of control, forming a mass called a tumor (Weitz et al., 2005). The global incidence of colon and rectum cancer estimated in 2020 was approximately 1880700 new cases and 915900 cancer deaths (Figure 1). The relative survival rate for colorectal cancer is 64% at 5-year following diagnosis and 58% at 10 years (Siegel et al., 2020). This can be determined by resistance to DDP, which may compromise the efficacy of chemotherapy, and some miRs related are described in Table 5.

TABLE 5.

MicroRNAs involved in DDP-chemoresistance of colorectal cancer.

miR Target Model Expression References
miR-125b-5p HK2 in vitro: HT29, SW620, HCT 116, SW480 & DLD-1 cells Down Shi et al. (2020)
in vivo: 35 colorectal cancer patients
miR-137 Not reported in vitro: SW480, HT-29, SW620 and LoVo cells Down Zheng et al. (2021a)
miR-148a WNT10b in vitro: SW480/DDP cells Down Shi et al. (2019)
in vivo: 90 colorectal cancer specimens
miR-155 FOXO3 in vitro: SW620 cells Up Gao et al. (2018)
in vivo: Samples from patients with colorectal cancer
miR-487a-3p SOX9 in vitro: HT29, SW480, SW620 & HCT 116 cells Up Sun et al. (2020c)
in vivo: 6 colorectal cancer tumor tissues
miR-490-3p TNKS2 in vitro: SW480, LoVo, DLD-1, SW48, RKO, HCT 116, HT29, SW620 & HCT 8 cells Down Li et al. (2021a)
in vivo: Samples of 162 colorectal cancer patients
miR-497 Bcl-2 in vitro: HCT 8/DDP cells Down Zheng et al. (2021c)
IGF1-R in vitro: HCT 116, LoVo, COLO 205, SW480 & SW620 cells Down Guo et al. (2013)
in vivo: Colorectal cancer patient samples
miR-526b-3p KLF12 in vitro: HCT 116/DDP and LoVo/DDP/DDP cells Down Zhang et al. (2021)
in vivo: Colorectal cancer tissue obtained from 37 patients
miR-593-5p CCND1 in vitro: SW1463, HR-8348 & SW837 cells Down Qu et al. (2020)
miR-645 SOX30 in vitro: Caco-2, LIM1215, COLO 205, SW620, HCT 116, SW480, LIM 1863, EB & WiDr cells Up Guo et al. (2017)
in vivo: Colorectal cancer tissue
miR-4486 ATG7 in vitro: HCT 116/DDP & SW480/DDP cells Down Wang et al. (2021c)
Open in a new tab

3 MicroRNAs Involved in DDP-Chemoresistance

3.1 MicroRNAs Involved in Cell Cycle

The cell cycle is a highly and complex mechanism that ensures complete and accurate cell division, and it is driven by several proteins named CDKs, which in turn are positively regulated by cyclins (A-E) and negatively regulated by CDKIs (1-9) (Sherr and Roberts, 1999); and also by MDMs (Flores and Sobrevia, 2000). Cells can acquire drug resistance due to a relative insensitivity to a chemotherapeutic agent because of the position of the cells in the cell cycle (Shah and Schwartz, 2001). Mechanistically, some miRs can target multiple proteins involved in cell cycle progression. Cisplatin-resistant colorectal cancer cell lines, HCT 116/DDP and LoVo/DDP, have been shown to express low levels of miR-526-3p, compared with parental cells, and silencing of miR-526b-3p increases cyclin D1 expression and reduced cell cycle arrest, promoting thus DDP-resistance in colorectal cancer cells enhances (Zhang et al., 2021). Mechanistically, miR-526-3p targeted KLF12. This is important, due to KLF12 is able to regulate cell death, by promoting the cell cycle transition through S phase and therefore cell proliferation and reduced expression levels of KLF12 results in increased ability of lung cancer cells to form tumors in vivo (Godin-Heymann et al., 2016). Another miRs involved in cell cycle is miR-25. High levels of miR-25 are found in several lung cancer cells (Zhao et al., 2014). Also, tumor-derived cells express elevated cyclin E2 levels, which accelerated cell cycle in G1 stage (Gudas et al., 1999). However, downregulation of miR-25 is able to induce cell cycle arrest by reducing CDK2 and cyclin E2 expression in lung cancer cells, thus sensitizing cells to DDP (Zhao et al., 2014). Roundabout guidance receptor 1 (ROBO1), a cancer-promoting oncogene, has been negatively correlated with the prognosis of patients, due to ROBO1 promotes the genesis and progression of cancer metastasis (Li et al., 2013). On this basis, miR-32 and miR-548a have proved to target the 3′-UTR sequence of ROBO1, promoting ROBO1 expression and activating the Wnt/β-catenin pathway. In addition, lung cancer cells exhibit low miR-32 and miR-548a levels, leading to an enhanced ROBO1 expression and displaying a DDP-resistant phenotype in A-549 cells (Zheng J. et al., 2021). In the same way, tankyrase 1 and 2 (TNKS1/2) are regulators of Wnt signaling by controlling the activity of the β-catenin destruction complex by reducing G1 cell cycle arrest and senescence (Foronda et al., 2019). Mechanistically, TNKS2 is targeted by miR-490-3p, and its increased expression promoted the chemoresistance of colorectal cancer cells (Li J. et al., 2021).

Likewise, levels of miR-103 are upregulated hepatocellular carcinoma cells (Luo et al., 2019), while miR-200a is reduced in DDP-resistant lung cancer cells (Tang et al., 2020). Also, NOR1 was targeted by miR-103 (Luo et al., 2019). It has been demonstrated that NOR1, a tumor suppressor gene, is downregulated in NPC cells and NOR1 that enhances cancer stem-like cell properties in tumor cells by enhancing the Akt and Wnt/β-catenin pathways (Wang et al., 2017). Additionally, miR-200a targeted β-catenin, regulating negatively its expression and its downstream molecules cyclin D1 and vimentin (Tang et al., 2020). Furthermore, cyclin D1 is also directly targeted by miR-593-5p in colorectal cancer cells (Qu et al., 2020) and by miR-1296 in breast cancer cells (Albakr et al., 2021). Cyclin D1 levels must be high during G1 phase for a cell to begin DNA synthesis, but then must be reduced to low levels during S phase to allow for efficient DNA synthesis, however, an aberrant cyclin D1 activity is observed in tumor cells (Montalto and De Amicis, 2020). Additionally, enhanced cyclin D1 and surviving expression enhance resistance by reducing G1 phase arrest and apoptosis, downregulating REV3L expression and leading to enhanced cell proliferation and invasive capacity (Zhu et al., 2016). Moreover, REV3L was targeted by miR-29a and miR-4458 and high expression was observed in tumoral tissues due to a decreased expression in lung cancer cells (Chen X. et al., 2019; Pang et al., 2020). However, overexpression of miR-29a could reduce viability and proliferation and enhance DDP-induced apoptosis of A-549/DDP cells treated with 5 μg/ml DDP (Chen X. et al., 2019).

Expression of miR-203 is enhanced in breast cancer cells, and, mechanistically, miR-203 targeted SOCS3, enhancing DDP-resistance (Ru et al., 2011). However, silencing of miR-203 sensitized breast cancer cells, and it was observed that those cells displayed a higher level of p21, associating these changes with decreased chemoresistance (Ru et al., 2011). This is important, due to p21 being a type of cell cycle regulator that plays a dual role in tumor cells, regulating the cell cycle, inducing apoptosis, and inhibiting cell proliferation (Wang L. et al., 2021). MDMs are nuclear factors that regulate the cell cycle at the G1/S phase transition, whose function and expression are altered in various types of human neoplasms (Momand et al., 1998). Degradation of p21 could be mediated by MDM4, in cooperation with MDM2, leading to abrogation of G1 cell cycle arrest (Jin et al., 2008). It has been reported that miR-1307 and miR-127-3p are downregulated in DDP-resistant breast cancer and lung cancer cell, respectively, and, mechanistically, they directly targeted MDM4 and MDM2, promoting DDP-resistance (Wang and Zhu, 2018; Zeng et al., 2020).

3.2 MicroRNAs involved in Autophagy

Autophagy is an intracellular self-digesting process for the regulation of cell homeostasis, that occurs under several stressful conditions, including organelle damage, the presence of abnormal proteins, and nutrient deprivation (Yun and Lee, 2018). In addition, autophagy regulates the properties of cancer stem-cells by contributing to the maintenance of stemness and the development of resistance to anticancer reagents (Yun and Lee, 2018). MiRs are involved in DDP response of tumor cells by regulation of autophagy.

A key initial event in autophagy is the formation of the autophagosome, and this step is mediated by the serine/threonine protein kinase ULK1 (Zachari and Ganley, 2017). Mechanistically, ULK1 is targeted by miR-514a-3p in NSCLC cells (Shen Q. et al., 2020). Moreover, miR-514a-3p was markedly downregulated in lung tissues and cells, and autophagy was found to be promoted (Shen Q. et al., 2020).

Autophagy-related (ATG) genes are indispensable for autophagosome formation, and enhanced autophagy and proliferation, and reduced apoptosis have been related to enhanced ATGs expression in cancer cells (Wang Q. et al., 2021). In this context, miR-17, miR-138-5p and miR-1236-3p enhances autophagy activity in lung cancer cells via ATG7 targeting (Huang FX. et al., 2019; Pan et al., 2019; Wang et al., 2020c). In addition, miR-4486 also enhances autophagy by targeting ATG7 in colorectal carcinoma cells (Wang W. et al., 2021). ATG3 is another key gene involved in autophagy and it is targeted by miR-1 in NSCLC cells (Hua et al., 2018). It has been observed that there was significant miR-1, miR-17, miR-138-5p and miR-1236-3p downregulation in NSCLC cells (Hua et al., 2018; Huang FX. et al., 2019; Pan et al., 2019; Wang et al., 2020c). Likewise, miR-4486 was also decreased in colorectal cancer cells (Wang W. et al., 2021). Moreover, miR-4443 is also upregulated in lung cancer cells. Besides, METTL3 was confirmed as a direct target gene of miR-4443 (Song et al., 2021). METTL3, a m6A methyltransferase, is able to regulate autophagy by increasing the critical genes, such as ATG5 and ATG7 (Liu S. et al., 2020). In this way, enhanced ATG7 levels promote the conversion of LC3-I into LC3-II and improve Beclin-1 expression, supporting autophagy and chemoresistance of lung cancer (Huang FX. et al., 2019; Wang et al., 2020c) and colorectal cancer cells (Wang W. et al., 2021). Beclin-1 also plays an important role in autophagy-induced tumorigenesis and drug resistance, altering cell growth, cellular microenvironment and cell division (Usman et al., 2021). Beclin-1 has been reported to be targeted by miR-30a in liver cancer cells (Zou et al., 2012) and by miR-216b in lung cancer cells (Chen L. et al., 2019), and both miRs are downregulated in both cancer types, suggesting their role in autophagy activity.

Moreover, miR-99a-5p was found to be upregulated in DDP-resistant gastric cancer cells (Sun G. et al., 2020). Mechanistically, miR-99a-5p targeted MTMR3 and enhanced MTMR was confirmed to induce autophagic activity (Taguchi-Atarashi et al., 2010), promoting resistance to chemotherapy in tumors.

3.3 MicroRNAs Involved in Epithelial-to-Mesenchymal Transition

The initiation of metastasis involves an increase in cell motility mediated by loss of cell-cell adhesion, caused by E-cadherin repression and augmented N-cadherin expression, in a process commonly known as epithelial-to-mesenchymal transition (EMT) (Taylor et al., 2010). In this way, high invasive potential, decreased E-cadherin expression and increased DDP-resistance has been founded in lung NCI-H1299, H596 and NCI-H522 cancer cells, due to a reduced miR-200c expression (Ceppi et al., 2010), and in liver Hep-G2 and Huh-7 cancer cells, also due to a decreased miR-31-5p expression (Chen et al., 2020).

A molecule implicated in the EMT process is polycomb ring finger (BMI1). Enhanced BMI1 expression, a known proto-oncogene, promoted EMT, augmented stemness and rendered cell drug resistance (Paranjape et al., 2014). On this basis, it has been reported that miR-802 expression is downregulated in DDP-resistant gastric cancer tissues and cells. Mechanistically, miR-802 directly targeted BMI1 and their boosted levels in gastric cancer cells promote EMT process (Liu et al., 2020d).

Zinc finger E-box binding homeobox 1 and 2 (ZEB1 and ZEB2) are transcription factors that promote tumor invasion and metastasis by inducing EMT in carcinoma cells (Zhang P. et al., 2015; DaSilva-Arnold et al., 2019). Also, ZEB1 has been founded to be targeted by miR-574-3p (Wang M. et al., 2019), while ZEB2 is targeted by miR-200c in gastric cancer cells (Jiang T. et al., 2017) and their upregulation contributed to DDP-resistance. Both miRs were founded to be downregulated in SGC-7901/DDP cells (Jiang T. et al., 2017; Wang M. et al., 2019). Even more, miR-223, miR-363 and miR-500a-3p directly targeted F-box and WD repeat domain containing 7 (FBXW7) and promote DDP-resistance in gastric cancer cells (Zhang et al., 2016; Wang et al., 2020b; Lin et al., 2020). FBXW7 (also known as FBW7) directly binds and degrades the EMT-inducing transcription factor ZEB2 in a phosphorylation-dependent manner and its loss can induce an EMT phenotype (Li N. et al., 2019). However, since miR-363 and miR-500a-3p are upregulated in gastric cancer MGC-803 and HGC-27 cells, and miR-223 in lung cancer A-549, NCI-H358 and NCI-H1299 cells, those cell lines display an EMT phenotype (Zhang et al., 2016; Wang et al., 2020b; Lin et al., 2020).

Another molecule that participated in the EMT process is doublecortin-like kinase 1 (DCLK1), a cancer stem cell marker. DCLK1 is functionally involved in maintaining cancer stemness and the process of EMT (Chandrakesan et al., 2016). Also, DCLK1 has been found to be targeted by miR-330-5p and its upregulation contributes to DDP-resistance. Likewise, miR-330-5p was found to be downregulated in lung cancer A-549 and NCI-H1299 resistant cells, promoting DDP-resistance in lung cancer cells (Ge et al., 2021).

Melanoma-associated antigen A3 (MAGEA3) enhances migration, invasion and proliferation by activation of EMT and Wnt signaling pathway in HeLa cells (Gao et al., 2020). In the same way, enhanced expression of MAGEA3 was found in drug-resistant cells (Bertram et al., 1998) and knockdown of MAGEA3 expression caused a reduction in proliferation and colony formation ability (Xie et al., 2016). Mechanistically, MAGEA3 is targeted by miR-31-5p, and its upregulation is associated with DDP-resistance. Likewise, miR-31-5p was founded to be downregulated in liver Hep-G2 and Huh-7 cancer cells, thus promoting DDP-resistance (Chen et al., 2020).

Collagen 1A1 (COL1A1) has been highly expressed and associated with poor prognosis in multiple cancers and positively correlated with the abundance of CAFs, macrophages, and tumor-infiltrating lymphocytes, and activation of EMT process (Liu et al., 2021). Also, miR-29b-3p directly target COL1A1 to promote DDP-resistance. Parallel that, it has been reported miR-29a-3p expression was reduced in lung A-549 cancer resistant cells, and augmented COL1A1 levels are associated with DDP-resistance (Jia and Wang, 2020).

Six homeobox 1 (SIX1) and Notch receptor 2 (NOTCH2) protein expressions have been associated with invasive lung cancer, by inducing EMT and thus promoting advanced malignant phenotypes (Mimae et al., 2012). Expression of miR-186-5p was downregulated lung A-549/DDP and NCI-H1299 resistant cancer cells. In addition, miR-186-5p negatively regulated SIX1 and SIX1 was upregulated in DDP resistant cancer cells (Liu X. et al., 2020).

SRY-related high mobility group-box 9 (SOX9) is a transcription factor, which acts as a proto-oncogene, implicated with the Wnt/β-catenin pathway activation and in the expression of EMT-associated proteins (Huang JQ. et al., 2019; Panda et al., 2021). Mechanistically, SOX9 is targeted by miR-487a-3p in colorectal cancer cells. Additionally, colorectal cancer cells displayed low miR-487a-3p levels, promoting SOX9 expression in colorectal HT29 and SW480 cells, exhibiting the DDP-resistant phenotype (Sun Y. et al., 2020).

Paxillin (PXN) is a cytoplasmatic protein which regulates focal adhesion. Also, PXN has been shown to promote the activation of ERK and enhance the EMT process (Wen et al., 2020). Bioinformatic analysis has proved that PXN is a direct target of miR-199b-5p. Also, decreased miR-199b-5p levels are observed in breast cancer cells, promoting the EMT process by reducing E-cadherin levels (Du et al., 2020). Loss of E-cadherin has been shown to promote the growth, invasion, and enhance drug resistance of CrC cells and, contribute to the progression and metastatic dissemination (Chen et al., 2012).

EIF5A2 plays an important role in many biological processes, including tumor formation, cancer cell growth, maintenance of cancer stem cells and EMT process (Meng et al., 2019). Bao et al. (2020) demonstrated EIF5A2 was targeted by miR-9 and was upregulated in lung tumor cells, thus promoting chemoresistance to DDP by increasing EMT process. Also, Wnt10b has been involved in enhanced tumor cell stemness by upregulation of OCT4 and NANOG expression. In colorectal cancer, WNT10b is directly targeted by miR-148a and the reduced miR-148a expression enhances Wnt10b levels to allow drug resistance in cancer therapy (Shi et al., 2019).

3.4 MicroRNAs Involved in Apoptosis

Apoptosis is a form of programmed cell death. In this pathway, molecular mechanisms which trigger inhibition of apoptosis responsible for DDP-resistance includes MAPK dysregulation, enhanced Bcl-2 or Bcl-XL expression, suppression of caspase-3 activity, enhanced PI3K/Akt activity, and so on (Siddik, 2003). A number of miRs have been described to be involved in the regulation of apoptosis.

Mitogen-activating protein kinases (MAPK) are molecules involved in apoptosis. There are three major MAPK pathways that involve the extracellular signal-regulated kinases: ERK1/2, JNK and p38 kinase. Chen et al., proved that MAPK3 was directly targeted by miR-206 in gastric cancer cells (Chen Z. et al., 2019). Also, Sun T. et al. (2020) demonstrated that miR-325-3p interacted with GITR, and upregulated expression contributes to DDP-resistance in gastric cancer cells. On this basis, GITR is able to enhance ERK phosphorylation, suggesting that GITR is associated whit MAPK-pathway activation (Ronchetti et al., 2004). Also, Rao et al. (2019) showed that miR-219a-5p directly targeted FGF9, and its enhanced expression leads to DDP-resistance in lung cancer cells. In this way, the low miR-325-3p and miR-219a-5p expression observed in gastric and lung cancer cells activate MAPK pathway, contributing to DDP-resistance (Ronchetti et al., 2004; Rao et al., 2019). Also, Zhou and Chen demonstrated that miR-135b interacted with MST1, and upregulated expression activates MAPK pathway, contributing to DDP-resistant phenotype (Zhou and Chen, 2019).

The intrinsic-mediated apoptotic pathway causes mitochondrial membrane potential loss, cytochrome c release and cleaved caspase-3. Bcl-2 is located in the mitochondrion membrane, and is related to the mitochondrial membrane potential loss and the cytochrome c release (Chen et al., 2015). MiR-7, miR-145, miR-146a, miR-152, miR-181b, miR-200b, miR-200c, miR-429, miR-451, miR-497 and miR-630 are reported to target Bcl-2 in lung cancer tissues and/or cells, and negatively regulate its expression (Zhu et al., 2010; Bian et al., 2011; Zhu et al., 2012a; Zhu et al., 2012b; Cheng et al., 2017; Pang et al., 2017; Chen et al., 2018; Zhang et al., 2019; Zhao et al., 2019). Likewise, miR-497 also interacts with Bcl-2 in colorectal cancer cells (Zheng ZH. et al., 2021). In this way, the low miR-7, miR-152, miR-181b, miR-200b, miR-200c, miR-429, miR-497 and miR-630 expression shown leads to decreased apoptosis incidence, resulting in a DDP-resistant phenotype in lung and colorectal cancer cells. Also, increased Bcl-2 levels have been associated with decreased cleaved-caspase 3 and E-cadherin levels, triggering EMT process and promoting DDP-phenotype (Du et al., 2020). The E2F family consists of 8 genes and 10 protein products encoded by these genes, which are crucial for regulating apoptosis, and they have been classified as transcriptional activators (E2F1-3), predicted to be oncogenic, or transcriptional repressors (E2F4-8), predicted to have tumor suppressor functions (Xie et al., 2021). E2Fs have been associated with the upregulation of Bcl-2, which contributes to uncontrolled tumor growth (Donzelli et al., 2012; Zheng et al., 2020; Zhou, 2020; Wu et al., 2021). In this context, miR-432 and miR-503 suppress E2F3 (Chen L. et al., 2016; Zhou, 2020), miR-34c targets E2F1 (Zheng et al., 2020), and miR-128-2 interacts with E2F5 (Donzelli et al., 2012), by targeting their 3′UTR mRNA. The reduced miR-432 and miR-34c expression observed in lung and gastric cancer cells were associated with advanced tumor stage and mortality and allowed E2F1 and E2F3 to be overexpressed in DDP-resistant phenotype (Chen L. et al., 2016; Zheng et al., 2020). Another molecule implicated in apoptosis is ID1. ID1 regulates p53 and NF-κB pathways, regulating Bax and Bcl-2 genes, thus providing a survival advantage under drug treatment (Kim et al., 2008). In this sense, miR-381 directly targeted ID1 and the reduced miR-381 levels observed in lung cancer cells allows an enhanced ID1 expression, reducing apoptosis and triggering a DDP-resistant phenotype (Huang et al., 2018). Finally, JNK2 negatively regulates the activity of genes related to tumor suppression and the induction of cell apoptosis (Chen et al., 2002). Regarding that, JNK2 was identified as a direct target of miR-146a and the low miR-146a levels reduced the apoptosis rate and enhanced the relative invasion rate of lung cancer cells (Pang et al., 2017).

The PI3K-Akt pathway is a major survival pathway activated in cancer. In this sense, phosphatase and tensin homolog (PTEN) is a molecule capable of inactivate the Akt signaling pathway and acts as a negative regulator of PI3K/Akt signaling (Georgescu, 2010). Also, PTEN/PI3K/Akt pathway regulates the signaling of multiple biological processes, such as apoptosis, and also enhances PI3K/Akt/mTOR pathway, conferring drug resistance and further cancer progression in breast cancer cells (Dong et al., 2021). MiR-18a, miR-19a, miR-21, miR-25-3p, miR-130b and miR-1269b in lung cancer cells (Xiao et al., 2018; Zhang et al., 2018; Xing et al., 2019; Yang W. et al., 2020; Gu et al., 2020; Sun B. et al., 2021; Liang et al., 2021), and miR-21 and miR-106a in gastric cancer cells (Fang et al., 2013; Yang et al., 2013; Zheng et al., 2017) directly regulate PTEN, and reduced miRs levels expression in cancer cells promote PTEN expression, triggering apoptosis and DDP-resistance. Additionally, HMGA2 and KLF4 regulation are able to promote PI3K/Akt phosphorylation, resulting in increased drug resistance (Deng et al., 2021), and miR-26a interacts with HMGA2 (Yang et al., 2016) and miR-145 with KLF4 (Cui et al., 2018) to promote DDP-resistance in lung cancer cells. Moreover, MET, a proto-oncogene, also activates PI3K/Akt pathway via promoting PTEN and CDKN1A expression and reducing apoptosis (Ohta et al., 2015). In this way, miR-206 regulates MET protein in A-549 lung cancer cells by directly targeting MET 3′-UTR and activated MET/PI3K/Akt/mTOR signaling pathway to induce DDP resistance (Chen QY. et al., 2016). To contribute to Akt activation and DDP-resistance, PI3K also is targeted by miR-10a (Huang T. et al., 2020). In the same way, two downstream effectors of the PI3K/Akt pathway are also regulated by miRs. Mammalian target of rapamycin (mTOR) acts as a target gene of miR-100-5p in lung cancer (Qin et al., 2017) controlling cell growth, proliferation and survival (Populo et al., 2012). Besides, FOXO3 also is regulated by miR-155 in colorectal cancer cells (Gao et al., 2018) and by miR-372 in gastric cancer cells (Wang C. et al., 2020), and enhanced FOXO3 expression by Akt promotes cell survival and resistance (Populo et al., 2012). Even more, miR-155-5p also targets PDK1 in liver cancer (Li et al., 2021c). It has been shown that PDK1 and PDK2 cause phosphorylation and activation of Akt after its translocation to inner membrane, modulating the function of numerous substrates involved in the regulation of cell survival, cell cycle progression and cellular growth (Fresno Vara et al., 2004). So, enhanced expression of miR-155-5p increases cell proliferation and reduces apoptosis of Hep3B2.1-7 liver cancer cells (Li et al., 2021c).

Other signal transductions involved in DDP-resistance are the nuclear factor (NF)-κB and apoptosis-related signaling pathways. NF-κB is known to play an important role in cell survival and inflammation. Several miRs have been reported to regulate NF-κB, such as miR-146a, miR-152 and miR-381 in lung cancer cells (Jiang P. et al., 2017; Huang et al., 2018; Zhao et al., 2019). Reduced expression of miR-146a (Jiang P. et al., 2017), miR-152 (Zhao et al., 2019) and miR-381 (Huang et al., 2018) is observed in DDP-resistant A-549 cells, which gives rise to a heightened NF-κB expression and promotes DDP-resistant phenotype. Moreover, another study demonstrated that GSTP1 was able to interact with IKKβ to activate NF-κB and induced the expression and release of IL-6, thus mediating drug resistance in breast cancer cells (Dong et al., 2020). Furthermore, miR-133b was diminished in DDP-resistant lung cells (Lin et al., 2018). Finally, miR-362 and miR-505 overexpression were observed in gastric cancer cells (Xia et al., 2014; Wang Z. et al., 2020), and their enhanced expression promoted nuclear accumulation of NF-κB/p65, due to both miRs targeted CYLD directly and its downregulation mediated NF-κB activation. Besides, Zhang and Luo found that miR-29c was downregulated in HepG2/DDP cells, and demonstrated that miR-29c targeted SIRT1 (Zhang and Luo, 2018). SIRT1 may have enhanced activity in tumor cell growth by promoting NF-κB expression (Yeung et al., 2004).

The Wnt/β-catenin signaling pathway participates in various physiological processes such as proliferation, differentiation, apoptosis, migration and invasion; on the other hand, dysregulation of the Wnt/β-catenin contributes to the development and progression of some solid tumors (Ge and Wang, 2010). Mir-130b, miR-140-3p, miR-326, and miR-1249 directly enhance the noncanonical Wnt pathway in liver and lung cancer cells (Zhang et al., 2018; Wu S. et al., 2020; Carotenuto et al., 2020; Wu Y. et al., 2020). Also, SOX30, a tumor suppressor, acts as a transcription factor by binding directly to the p53 promoter and reduces SOX30 expression, resulting in enhanced β-catenin expression and Wnt/β-catenin pathway activation (Liu et al., 2020c). Guo et al. (2017) demonstrated miR-645 directly targeted SOX30 in colorectal cancer cells, enhancing DDP-resistant phenotype.

Other molecules also have been reported to confer DDP-resistance by inhibiting apoptosis. CYP1B1, a cytochrome P450 enzyme, is overexpressed in malignant ovarian cancer (Zhu et al., 2015). MiR-513a-3p had the same binding site to CYP1B1, low miR-513a-3p levels enhance CYP1B1 expression, conferring DDP-resistance by reducing DDP-induced apoptosis in gastric cancer cells (Cheng et al., 2021). ROCK1 and ROCK2 proteins are narrowly associated with tumor progress and lymph node metastasis (Zhang J. et al., 2015). Moreover, ROCK2 was regulated by miR-142-3p, and its reduced levels enhance ROCK2 expression, resulting in a DDP-resistant phenotype by reducing DDP-induced apoptosis in gastric cancer cells (Peng et al., 2020).

3.5 MicroRNAs Involved in Drug Efflux

The reduced uptake of water-soluble drugs and augmented drug efflux from cancer cells are the biochemical and cytological mechanisms of drug resistance in cancer cells (Chen et al., 2015). P-glycoprotein (P-gp, also known as MDR1) is encoded by the multidrug resistance gene (ABCB1). P-gp acts as a drug pump and it can bind to several drugs and pump them out of the cells, thereby decreasing their intracellular concentration and the sensitivity of cancer cells to the drug (Breier et al., 2005). P-gp is influenced by miR-30 and miR-129 in gastric cancer cells (Lu et al., 2017; Du et al., 2018), and by miR-144-3p, miR-145, and miR-202-5p in lung cancer cells (Tian et al., 2019; Zhang et al., 2019; Shen JG. et al., 2020).

Also, two additional ABC transporters, the multidrug resistance-associated protein 1 (MRP1; encoded by ABCC1), and ABCG2 are also implicated in multidrug resistance (Robey et al., 2018). Mechanistically, ABCC1 was targeted by miR-185-5p and negatively regulated its expression in lung cancer cells (Pei et al., 2016). Additionally, miR-144-3p and miR-145 also influenced the expression of MRP1 in lung cancer cells (Tian et al., 2019; Zhang et al., 2019), and by miR-381 in breast cancer cells (Yi et al., 2019) thus contributing to DDP-resistant phenotype.

4 Conclusion and Future Perspectives

Resistance to DDP is a major challenge that hampers the success of cancer treatment. According to current knowledge, multiple factors such as DNA damage and repair, transport process, autophagy, and apoptosis are involved in resistance to platinum-based drugs. Some dysregulated miRs functioned as an oncogenic molecules and others acted as a tumor repressor, and we tried to provide a general vision about this effect. Understanding the underlying molecular mechanisms of DDP-resistance is fundamental to reverse chemoresistance. In this way, it is possible to develop strategies to identify biomarkers of drug response and resistance, being useful in future clinical trials and rational management of cancer patients (Figure 2). Vast evidence shows that specific miRs can be regulated and then targets downstream genes to re-sensitize cancer cells to the effects of DDP. For example, lidocaine alleviates DDP-resistance of MGC-803/DDP gastric cancer cells, inhibiting their migration through decreasing miR-10b expression (Zhang X. et al., 2020). Besides, the use nanoliposomes loaded with miR-1296 sensitizes breast cancer cells to DDP, by reducing CCND1, and thus, EMT process (Albakr et al., 2021). Finally, curcumin treatment is able to restrain the proliferation and facilitated apoptosis in HCT8/DDP cells, by promoting miR-497/Bcl-2 axis (Zheng ZH. et al., 2021). Consequently, it is just a matter of time until miR-based therapies be proved to restore the sensitivity of tumor cells to some anticancer drugs including DDP.

FIGURE 2.

FIGURE 2

Open in a new tab

Venn diagram showing the common microRNAs expressed in the top five deadliest cancer. Upregulated microRNAs are highlighted in red color, whereas downregulated ones are in blue color.

In this review, we have summarized some of our current understanding of microRNAs that affect DDP-resistance and some strategies that have been employed to sensitize cancer cells to DDP chemotherapy. These studies have improved our understanding of the involvement of miRs in drug resistance and provide a starting point for the development of ncRNA-based therapy to accelerate the resolution of DDP-resistance in many cancers, to improve the quality of life and prognosis of patients.

Author Contributions

PL, NS, and KS contributed to the conception of the summarize, performed the data analyses and wrote the manuscript. NT and MV performed figures and tables. NT, PM, and LS reviewed and edited the manuscript. All authors read and approved the manuscript.

Funding

This research was funded by ANID-FAPESP (Grant No. 19/13250-1), FONDECYT (Grant No. 1171765), Programa de Formación de Investigadores Postdoctorales, VRIP, Universidad de La Frontera, Temuco, Chile (Code VRIP 21001) and FONDECYT Postdoctoral Grant No. 3220404 awarded to PL.

Conflict of Interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  1. Albakr L., Alqahtani F. Y., Aleanizy F. S., Alomrani A., Badran M., Alhindas H., et al. (2021). Improved Delivery of miR-1296 Loaded Cationic Nanoliposomes for Effective Suppression of Triple Negative Breast Cancer. Saudi Pharm. J. 29 (5), 446–455. 10.1016/j.jsps.2021.04.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Amable L. (2016). Cisplatin Resistance and Opportunities for Precision Medicine. Pharmacol. Res. 106, 27–36. 10.1016/j.phrs.2016.01.001 [DOI] [PubMed] [Google Scholar]
  3. Anwanwan D., Singh S. K., Singh S., Saikam V., Singh R. (2020). Challenges in Liver Cancer and Possible Treatment Approaches. Biochim. Biophys. Acta Rev. Cancer 1873 (1), 188314. 10.1016/j.bbcan.2019.188314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Ashrafizadeh M., Zarrabi A., Hushmandi K., Kalantari M., Mohammadinejad R., Javaheri T., et al. (2020). Association of the Epithelial-Mesenchymal Transition (EMT) with Cisplatin Resistance. Int. J. Mol. Sci. 21 (11), 4002. 10.3390/ijms21114002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bao Y., Zhang Y., Lu Y., Guo H., Dong Z., Chen Q., et al. (2020). Overexpression of microRNA-9 Enhances Cisplatin Sensitivity in Hepatocellular Carcinoma by Regulating EIF5A2-Mediated Epithelial-Mesenchymal Transition. Int. J. Biol. Sci. 16 (5), 827–837. 10.7150/ijbs.32460 [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bar J., Gorn-Hondermann I., Moretto P., Perkins T. J., Niknejad N., Stewart D. J., et al. (2015). miR Profiling Identifies Cyclin-dependent Kinase 6 Downregulation as a Potential Mechanism of Acquired Cisplatin Resistance in Non-small-cell Lung Carcinoma. Clin. Lung Cancer 16 (6), e121–9. 10.1016/j.cllc.2015.01.008 [DOI] [PubMed] [Google Scholar]
  7. Beikman S., Gordon P., Ferrari S., Siegel M., Zalewski M. A., Rosenzweig M. Q. (2013). Understanding the Implications of the Breast Cancer Pathology Report: a Case Study. J. Adv. Pract. Oncol. 4 (3), 176–181. 10.6004/jadpro.2013.4.3.6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Bertram J., Palfner K., Hiddemann W., Kneba M. (1998). Elevated Expression of S100P, CAPL and MAGE 3 in Doxorubicin-Resistant Cell Lines: Comparison of mRNA Differential Display Reverse Transcription-Polymerase Chain Reaction and Subtractive Suppressive Hybridization for the Analysis of Differential Gene Expression. Anticancer Drugs 9 (4), 311–317. 10.1097/00001813-199804000-00004 [DOI] [PubMed] [Google Scholar]
  9. Bian H. B., Pan X., Yang J. S., Wang Z. X., De W. (2011). Upregulation of microRNA-451 Increases Cisplatin Sensitivity of Non-small Cell Lung Cancer Cell Line (A549). J. Exp. Clin. Cancer Res. 30, 20. 10.1186/1756-9966-30-20 [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Breier A., Barancík M., Sulová Z., Uhrík B. (2005). P-glycoprotein--implications of Metabolism of Neoplastic Cells and Cancer Therapy. Curr. Cancer Drug Targets 5 (6), 457–468. 10.2174/1568009054863636 [DOI] [PubMed] [Google Scholar]
  11. Bukowski K., Kciuk M., Kontek R. (2020). Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int. J. Mol. Sci. 21 (9), 3233. 10.3390/ijms21093233 [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Carotenuto P., Hedayat S., Fassan M., Cardinale V., Lampis A., Guzzardo V., et al. (2020). Modulation of Biliary Cancer Chemo-Resistance through MicroRNA-Mediated Rewiring of the Expansion of CD133+ Cells. Hepatology 72 (3), 982–996. 10.1002/hep.31094 [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ceppi P., Mudduluru G., Kumarswamy R., Rapa I., Scagliotti G. V., Papotti M., et al. (2010). Loss of miR-200c Expression Induces an Aggressive, Invasive, and Chemoresistant Phenotype in Non-small Cell Lung Cancer. Mol. Cancer Res. 8 (9), 1207–1216. 10.1158/1541-7786.MCR-10-0052 [DOI] [PubMed] [Google Scholar]
  14. Chandrakesan P., Panneerselvam J., Qu D., Weygant N., May R., Bronze M. S., et al. (2016). Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells. J. Carcinog Mutagen 7 (2). 10.4172/2157-2518.1000257 [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Chekhun V. F., Lukyanova N. Y., Burlaka C. A., Bezdenezhnykh N. A., Shpyleva S. I., Tryndyak V. P., et al. (2013). Iron Metabolism Disturbances in the MCF-7 Human Breast Cancer Cells with Acquired Resistance to Doxorubicin and Cisplatin. Int. J. Oncol. 43 (5), 1481–1486. 10.3892/ijo.2013.2063 [DOI] [PubMed] [Google Scholar]
  16. Chen D., Ping S., Xu Y., Wang M., Jiang X., Xiong L., et al. (2021). Non-Coding RNAs in Gastric Cancer: From Malignant Hallmarks to Clinical Applications. Front Cel Dev Biol 9, 732036. 10.3389/fcell.2021.732036 [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Chen L., Han X., Hu Z., Chen L. (2019). The PVT1/miR-216b/Beclin-1 Regulates Cisplatin Sensitivity of NSCLC Cells via Modulating Autophagy and Apoptosis. Cancer Chemother. Pharmacol. 83 (5), 921–931. 10.1007/s00280-019-03808-3 [DOI] [PubMed] [Google Scholar]
  18. Chen L., Kong G., Zhang C., Dong H., Yang C., Song G., et al. (2016a). MicroRNA-432 Functions as a Tumor Suppressor Gene through Targeting E2F3 and AXL in Lung Adenocarcinoma. Oncotarget 7 (15), 20041–20053. 10.18632/oncotarget.7884 [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chen M. J., Wu D. W., Wang G. C., Wang Y. C., Chen C. Y., Lee H. (2018). MicroRNA-630 May Confer Favorable Cisplatin-Based Chemotherapy and Clinical Outcomes in Non-small Cell Lung Cancer by Targeting Bcl-2. Oncotarget 9 (17), 13758–13767. 10.18632/oncotarget.24474 [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Chen N., She Q. B., Bode A. M., Dong Z. (2002). Differential Gene Expression Profiles of Jnk1- and Jnk2-Deficient Murine Fibroblast Cells. Cancer Res. 62 (5), 1300–1304. [PubMed] [Google Scholar]
  21. Chen Q. Y., Jiao D. M., Wang J., Hu H., Tang X., Chen J., et al. (2016). miR-206 Regulates Cisplatin Resistance and EMT in Human Lung Adenocarcinoma Cells Partly by Targeting MET. Oncotarget 7 (17), 24510–24526. 10.18632/oncotarget.8229 [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Chen X., Wang Y., Xia H., Wang Q., Jiang X., Lin Z., et al. (2012). Loss of E-Cadherin Promotes the Growth, Invasion and Drug Resistance of Colorectal Cancer Cells and Is Associated with Liver Metastasis. Mol. Biol. Rep. 39 (6), 6707–6714. 10.1007/s11033-012-1494-2 [DOI] [PubMed] [Google Scholar]
  23. Chen X., Zhu H., Ye W., Cui Y., Chen M. (2019). MicroRNA-29a E-nhances C-isplatin S-ensitivity in N-on-small C-ell L-ung C-ancer through the R-egulation of REV3L. Mol. Med. Rep. 19 (2), 831–840. 10.3892/mmr.2018.9723 [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Chen Y., Gao Y., Zhang K., Li C., Pan Y., Chen J., et al. (2015). MicroRNAs as Regulators of Cisplatin Resistance in Lung Cancer. Cell Physiol Biochem 37 (5), 1869–1880. 10.1159/000438548 [DOI] [PubMed] [Google Scholar]
  25. Chen Y., Zhao H., Li H., Feng X., Tang H., Qiu C., et al. (2020). LINC01234/MicroRNA-31-5p/MAGEA3 Axis Mediates the Proliferation and Chemoresistance of Hepatocellular Carcinoma Cells. Mol. Ther. Nucleic Acids 19, 168–178. 10.1016/j.omtn.2019.10.035 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  26. Chen Z., Gao Y. J., Hou R. Z., Ding D. Y., Song D. F., Wang D. Y., et al. (2019). MicroRNA-206 Facilitates Gastric Cancer Cell Apoptosis and Suppresses Cisplatin Resistance by Targeting MAPK2 Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci. 23 (1), 171–180. 10.26355/eurrev_201901_16761 [DOI] [PubMed] [Google Scholar]
  27. Cheng C., Qin Y., Zhi Q., Wang J., Qin C. (2018). Knockdown of Long Non-coding RNA HOTAIR Inhibits Cisplatin Resistance of Gastric Cancer Cells through Inhibiting the PI3K/Akt and Wnt/β-Catenin Signaling Pathways by Up-Regulating miR-34a. Int. J. Biol. Macromol 107 (Pt B), 2620–2629. 10.1016/j.ijbiomac.2017.10.154 [DOI] [PubMed] [Google Scholar]
  28. Cheng H., Sharen G., Wang Z., Zhou J. (2021). LncRNA UCA1 Enhances Cisplatin Resistance by Regulating CYP1B1-Mediated Apoptosis via miR-513a-3p in Human Gastric Cancer. Cmar 13, 367–377. 10.2147/CMAR.S277399 [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Cheng M. W., Shen Z. T., Hu G. Y., Luo L. G. (2017). Prognostic Significance of microRNA-7 and its Roles in the Regulation of Cisplatin Resistance in Lung Adenocarcinoma. Cel Physiol Biochem 42 (2), 660–672. 10.1159/000477884 [DOI] [PubMed] [Google Scholar]
  30. Cui Y., Li G., Zhang X., Dai F., Zhang R. (2018). Increased MALAT1 Expression Contributes to Cisplatin Resistance in Non-small Cell Lung Cancer. Oncol. Lett. 16 (4), 4821–4828. 10.3892/ol.2018.9293 [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. DaSilva-Arnold S. C., Kuo C. Y., Davra V., Remache Y., Kim P. C. W., Fisher J. P., et al. (2019). ZEB2, a Master Regulator of the Epithelial-Mesenchymal Transition, Mediates Trophoblast Differentiation. Mol. Hum. Reprod. 25 (2), 61–75. 10.1093/molehr/gay053 [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Deng X., Kong F., Li S., Jiang H., Dong L., Xu X., et al. (2021). A KLF4/PiHL/EZH2/HMGA2 Regulatory axis and its Function in Promoting Oxaliplatin-Resistance of Colorectal Cancer. Cell Death Dis 12 (5), 485. 10.1038/s41419-021-03753-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Dong C., Wu J., Chen Y., Nie J., Chen C. (2021). Activation of PI3K/AKT/mTOR Pathway Causes Drug Resistance in Breast Cancer. Front. Pharmacol. 12, 628690. 10.3389/fphar.2021.628690 [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Dong X., Sun R., Wang J., Yu S., Cui J., Guo Z., et al. (2020). Glutathione S-Transferases P1-Mediated Interleukin-6 in Tumor-Associated Macrophages Augments Drug-Resistance in MCF-7 Breast Cancer. Biochem. Pharmacol. 182, 114289. 10.1016/j.bcp.2020.114289 [DOI] [PubMed] [Google Scholar]
  35. Dong Z., Zhong Z., Yang L., Wang S., Gong Z. (2014). MicroRNA-31 Inhibits Cisplatin-Induced Apoptosis in Non-small Cell Lung Cancer Cells by Regulating the Drug Transporter ABCB9. Cancer Lett. 343 (2), 249–257. 10.1016/j.canlet.2013.09.034 [DOI] [PubMed] [Google Scholar]
  36. Donzelli S., Fontemaggi G., Fazi F., Di Agostino S., Padula F., Biagioni F., et al. (2012). MicroRNA-128-2 Targets the Transcriptional Repressor E2F5 Enhancing Mutant P53 Gain of Function. Cell Death Differ 19 (6), 1038–1048. 10.1038/cdd.2011.190 [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Du C., Wang Y., Zhang Y., Zhang J., Zhang L., Li J. (2020). LncRNA DLX6-AS1 Contributes to Epithelial-Mesenchymal Transition and Cisplatin Resistance in Triple-Negative Breast Cancer via Modulating Mir-199b-5p/Paxillin Axis. Cel Transpl. 29, 963689720929983. 10.1177/0963689720929983 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  38. Du X., Liu B., Luan X., Cui Q., Li L. (2018). miR-30 Decreases Multidrug Resistance in Human Gastric Cancer Cells by Modulating Cell Autophagy. Exp. Ther. Med. 15 (1), 599–605. 10.3892/etm.2017.5354 [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. El-Serag H. B., Marrero J. A., Rudolph L., Reddy K. R. (2008). Diagnosis and Treatment of Hepatocellular Carcinoma. Gastroenterology 134 (6), 1752–1763. 10.1053/j.gastro.2008.02.090 [DOI] [PubMed] [Google Scholar]
  40. Fang Y., Shen H., Li H., Cao Y., Qin R., Long L., et al. (2013). miR-106a Confers Cisplatin Resistance by Regulating PTEN/Akt Pathway in Gastric Cancer Cells. Acta Biochim. Biophys. Sin (Shanghai) 45 (11), 963–972. 10.1093/abbs/gmt106 [DOI] [PubMed] [Google Scholar]
  41. FDA (1978). Approval Summary for Cisplatin for Metastatic Ovarian Tumors. Silver Spring: FDA Oncology Tools. [Google Scholar]
  42. Ferlay J., Colombet M., Soerjomataram I., Parkin D. M., Piñeros M., Znaor A., et al. (2021). Cancer Statistics for the Year 2020: An Overview. Int. J. Cancer 149, 778–789. 10.1002/ijc.33588 [DOI] [PubMed] [Google Scholar]
  43. Flores C., Sobrevia L. (2000). Tumorogenesis and Mdm2 Protein. Rev. Med. Chil 128 (5), 539–546. 10.4067/S0034-98872000000500014 [DOI] [PubMed] [Google Scholar]
  44. Foronda M., Tarumoto Y., Schatoff E. M., Leach B. I., Diaz B. J., Zimmerman J., et al. (2019). Tankyrase Inhibition Sensitizes Cells to CDK4 Blockade. PLoS One 14 (12), e0226645. 10.1371/journal.pone.0226645 [DOI] [PMC free article] [PubMed] [Google Scholar]
  45. Fresno Vara J. A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., González-Barón M. (2004). PI3K/Akt Signalling Pathway and Cancer. Cancer Treat. Rev. 30 (2), 193–204. 10.1016/j.ctrv.2003.07.007 [DOI] [PubMed] [Google Scholar]
  46. Gao X., Chen G., Cai H., Wang X., Song K., Liu L., et al. (2020). Aberrantly Enhanced Melanoma-Associated Antigen (MAGE)-A3 Expression Facilitates Cervical Cancer Cell Proliferation and Metastasis via Actuating Wnt Signaling Pathway. Biomed. Pharmacother. 122, 109710. 10.1016/j.biopha.2019.109710 [DOI] [PubMed] [Google Scholar]
  47. Gao Y., Liu Z., Ding Z., Hou S., Li J., Jiang K. (2018). MicroRNA-155 Increases colon Cancer Chemoresistance to Cisplatin by Targeting Forkhead Box O3. Oncol. Lett. 15 (4), 4781–4788. 10.3892/ol.2018.7976 [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Ge P., Cao L., Zheng M., Yao Y., Wang W., Chen X. (2021). LncRNA SNHG1 Contributes to the Cisplatin Resistance and Progression of NSCLC via miR-330-5p/DCLK1 axis. Exp. Mol. Pathol. 120, 104633. 10.1016/j.yexmp.2021.104633 [DOI] [PubMed] [Google Scholar]
  49. Ge X., Liu X., Lin F., Li P., Liu K., Geng R., et al. (2016). MicroRNA-421 Regulated by HIF-1α Promotes Metastasis, Inhibits Apoptosis, and Induces Cisplatin Resistance by Targeting E-Cadherin and Caspase-3 in Gastric Cancer. Oncotarget 7 (17), 24466–24482. 10.18632/oncotarget.8228 [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Ge X., Wang X. (2010). Role of Wnt Canonical Pathway in Hematological Malignancies. J. Hematol. Oncol. 3, 33. 10.1186/1756-8722-3-33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Georgescu M. M. (2010). PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control. Genes Cancer 1 (12), 1170–1177. 10.1177/1947601911407325 [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Godin-Heymann N., Brabetz S., Murillo M. M., Saponaro M., Santos C. R., Lobley A., et al. (2016). Tumour-suppression Function of KLF12 through Regulation of Anoikis. Oncogene 35 (25), 3324–3334. 10.1038/onc.2015.394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  53. Gu Y., Fei Z., Zhu R. (2020). miR-21 Modulates Cisplatin Resistance of Gastric Cancer Cells by Inhibiting Autophagy via the PI3K/Akt/mTOR Pathway. Anticancer Drugs 31 (4), 385–393. 10.1097/CAD.0000000000000886 [DOI] [PubMed] [Google Scholar]
  54. Gu Y., Zhang Z., Yin J., Ye J., Song Y., Liu H., et al. (2017). Epigenetic Silencing of miR-493 Increases the Resistance to Cisplatin in Lung Cancer by Targeting Tongue Cancer Resistance-Related Protein 1(TCRP1). J. Exp. Clin. Cancer Res. 36 (1), 114. 10.1186/s13046-017-0582-5 [DOI] [PMC free article] [PubMed] [Google Scholar]
  55. Guan Y., Zhang Y., Hao L., Nie Z. (2020). CircRNA_102272 Promotes Cisplatin-Resistance in Hepatocellular Carcinoma by Decreasing MiR-326 Targeting of RUNX2. Cancer Manag. Res. 12, 12527–12534. 10.2147/CMAR.S258230 [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Gudas J. M., Payton M., Thukral S., Chen E., Bass M., Robinson M. O., et al. (1999). Cyclin E2, a Novel G1 Cyclin that Binds Cdk2 and Is Aberrantly Expressed in Human Cancers. Mol. Cel Biol 19 (1), 612–622. 10.1128/MCB.19.1.612 [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. Guo C., Dong G., Liang X., Dong Z. (2019). Epigenetic Regulation in AKI and Kidney Repair: Mechanisms and Therapeutic Implications. Nat. Rev. Nephrol. 15 (4), 220–239. 10.1038/s41581-018-0103-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Guo S. T., Guo X. Y., Wang J., Wang C. Y., Yang R. H., Wang F. H., et al. (2017). MicroRNA-645 Is an Oncogenic Regulator in colon Cancer. Oncogenesis 6 (5), e335. 10.1038/oncsis.2017.37 [DOI] [PMC free article] [PubMed] [Google Scholar]
  59. Guo S. T., Jiang C. C., Wang G. P., Li Y. P., Wang C. Y., Guo X. Y., et al. (2013). MicroRNA-497 Targets Insulin-like Growth Factor 1 Receptor and Has a Tumour Suppressive Role in Human Colorectal Cancer. Oncogene 32 (15), 1910–1920. 10.1038/onc.2012.214 [DOI] [PMC free article] [PubMed] [Google Scholar]
  60. He B., Wu C., Sun W., Qiu Y., Li J., Liu Z., et al. (2021). miR-383 I-ncreases the C-isplatin S-ensitivity of L-ung A-denocarcinoma C-ells through I-nhibition of the RBM24-mediated NF-κB S-ignaling P-athway. Int. J. Oncol. 59 (5), 87. 10.3892/ijo.2021.5267 [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. He J., Qi H., Chen F., Cao C. (2017). MicroRNA-25 Contributes to Cisplatin Resistance in Gastric Cancer Cells by Inhibiting Forkhead Box O3a. Oncol. Lett. 14 (5), 6097–6102. 10.3892/ol.2017.6982 [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. He X., Xiao X., Dong L., Wan N., Zhou Z., Deng H., et al. (2015). MiR-218 Regulates Cisplatin Chemosensitivity in Breast Cancer by Targeting BRCA1. Tumour Biol. 36 (3), 2065–2075. 10.1007/s13277-014-2814-z [DOI] [PubMed] [Google Scholar]
  63. Hu J., Lieb J. D., Sancar A., Adar S. (2016). Cisplatin DNA Damage and Repair Maps of the Human Genome at Single-Nucleotide Resolution. Proc. Natl. Acad. Sci. U S A. 113 (41), 11507–11512. 10.1073/pnas.1614430113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Hua G., Zeng Z. L., Shi Y. T., Chen W., He L. F., Zhao G. F. (2021). LncRNA XIST Contributes to Cisplatin Resistance of Lung Cancer Cells by Promoting Cellular Glycolysis through Sponging miR-101-3p. Pharmacology 106 (9-10), 498–508. 10.1159/000512621 [DOI] [PubMed] [Google Scholar]
  65. Hua L., Zhu G., Wei J. (2018). MicroRNA-1 Overexpression Increases Chemosensitivity of Non-small Cell Lung Cancer Cells by Inhibiting Autophagy Related 3-mediated Autophagy. Cell Biol Int 42 (9), 1240–1249. 10.1002/cbin.10995 [DOI] [PubMed] [Google Scholar]
  66. Huang F. X., Chen H. J., Zheng F. X., Gao Z. Y., Sun P. F., Peng Q., et al. (2019). LncRNA BLACAT1 Is Involved in Chemoresistance of Non-small C-ell L-ung C-ancer C-ells by R-egulating A-utophagy. Int. J. Oncol. 54 (1), 339–347. 10.3892/ijo.2018.4614 [DOI] [PubMed] [Google Scholar]
  67. Huang J. Q., Wei F. K., Xu X. L., Ye S. X., Song J. W., Ding P. K., et al. (2019). SOX9 Drives the Epithelial-Mesenchymal Transition in Non-small-cell Lung Cancer through the Wnt/β-Catenin Pathway. J. Transl Med. 17 (1), 143. 10.1186/s12967-019-1895-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  68. Huang R. S., Zheng Y. L., Zhao J., Chun X. (2018). microRNA-381 Suppresses the Growth and Increases Cisplatin Sensitivity in Non-small Cell Lung Cancer Cells through Inhibition of Nuclear Factor-Κb Signaling. Biomed. Pharmacother. 98, 538–544. 10.1016/j.biopha.2017.12.092 [DOI] [PubMed] [Google Scholar]
  69. Huang T., Ren K., Ding G., Yang L., Wen Y., Peng B., et al. (2020). miR-10a I-ncreases the C-isplatin R-esistance of L-ung A-denocarcinoma C-irculating T-umor C-ells via T-argeting PIK3CA in the PI3K/Akt P-athway. Oncol. Rep. 43 (6), 1906–1914. 10.3892/or.2020.7547 [DOI] [PMC free article] [PubMed] [Google Scholar]
  70. Huang X., Li Z., Zhang Q., Wang W., Li B., Wang L., et al. (2019). Circular RNA AKT3 Upregulates PIK3R1 to Enhance Cisplatin Resistance in Gastric Cancer via miR-198 Suppression. Mol. Cancer 18 (1), 71. 10.1186/s12943-019-0969-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  71. Huang X. X., Zhang Q., Hu H., Jin Y., Zeng A. L., Xia Y. B., et al. (2020). A Novel Circular RNA circFN1 Enhances Cisplatin Resistance in Gastric Cancer via Sponging miR-182-5p. J. Cel Biochem 122, 1009–1020. 10.1002/jcb.29641 [DOI] [PubMed] [Google Scholar]
  72. Jia R., Wang C. (2020). MiR-29b-3p Reverses Cisplatin Resistance by Targeting COL1A1 in Non-small-cell Lung Cancer A549/DDP Cells. Cancer Manag. Res. 12, 2559–2566. 10.2147/CMAR.S246625 [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Jiang J., Fang H., Sun W., Feng Y., Zhou L. (2020). Reversal of Drug Resistance in Gastric Cancer Cells by miR-503 and its Mechanism. Acta Med. Mediterranea 36, 1841–1848. 10.19193/0393-6384_2020_3_289 [DOI] [Google Scholar]
  74. Jiang P., Jia W., Wei X., Zhang X., Wang C., Li B., et al. (2017). MicroRNA-146a Regulates Cisplatin-Resistance of Non-small Cell Lung Cancer Cells by Targeting NF-Κb Pathway. Int. J. Clin. Exp. Pathol. 10 (12), 11545–11553. [PMC free article] [PubMed] [Google Scholar]
  75. Jiang P., Wu X., Wang X., Huang W., Feng Q. (2016). NEAT1 Upregulates EGCG-Induced CTR1 to Enhance Cisplatin Sensitivity in Lung Cancer Cells. Oncotarget 7 (28), 43337–43351. 10.18632/oncotarget.9712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  76. Jiang T., Dong P., Li L., Ma X., Xu P., Zhu H., et al. (2017). MicroRNA-200c Regulates Cisplatin Resistance by Targeting ZEB2 in Human Gastric Cancer Cells. Oncol. Rep. 38 (1), 151–158. 10.3892/or.2017.5659 [DOI] [PubMed] [Google Scholar]
  77. Jin X., Pang W., Zhang Q., Huang H. (2019). MicroRNA-486-5p Improves Nonsmall-Cell Lung Cancer Chemotherapy Sensitivity and Inhibits Epithelial-Mesenchymal Transition by Targeting Twinfilin Actin Binding Protein 1. J. Int. Med. Res. 47 (8), 3745–3756. 10.1177/0300060519850739 [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Jin Y., Zeng S. X., Sun X. X., Lee H., Blattner C., Xiao Z., et al. (2008). MDMX Promotes Proteasomal Turnover of P21 at G1 and Early S Phases Independently of, but in Cooperation with, MDM2. Mol. Cel Biol 28 (4), 1218–1229. 10.1128/MCB.01198-07 [DOI] [PMC free article] [PubMed] [Google Scholar]
  79. Kim H., Chung H., Kim H. J., Lee J. Y., Oh M. Y., Kim Y., et al. (2008). Id-1 Regulates Bcl-2 and Bax Expression through P53 and NF-kappaB in MCF-7 Breast Cancer Cells. Breast Cancer Res. Treat. 112 (2), 287–296. 10.1007/s10549-007-9871-6 [DOI] [PubMed] [Google Scholar]
  80. Kitamura H., Yazawa T., Sato H., Okudela K., Shimoyamada H. (2009). Small Cell Lung Cancer: Significance of RB Alterations and TTF-1 Expression in its Carcinogenesis, Phenotype, and Biology. Endocr. Pathol. 20 (2), 101–107. 10.1007/s12022-009-9072-4 [DOI] [PubMed] [Google Scholar]
  81. Ko T., Li S. (2019). Genome-wide Screening Identifies Novel Genes and Biological Processes Implicated in Cisplatin Resistance. FASEB J. 33 (6), 7143–7154. 10.1096/fj.201801534RR [DOI] [PubMed] [Google Scholar]
  82. Kozomara A., Birgaoanu M., Griffiths-Jones S. (2019). miRBase: from microRNA Sequences to Function. Nucleic Acids Res. 47 (D1), D155–D162. 10.1093/nar/gky1141 [DOI] [PMC free article] [PubMed] [Google Scholar]
  83. Li J., Chen Y., Jin M., Wang J., Li S., Chen Z., et al. (2017). MicroRNA-134 Reverses Multidrug Resistance in Human Lung Adenocarcinoma Cells by Targeting FOXM1. Oncol. Lett. 13 (3), 1451–1455. 10.3892/ol.2017.5574 [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Li J. H., Luo N., Zhong M. Z., Xiao Z. Q., Wang J. X., Yao X. Y., et al. (2016a). Inhibition of microRNA-196a Might Reverse Cisplatin Resistance of A549/DDP Non-small-cell Lung Cancer Cell Line. Tumour Biol. 37 (2), 2387–2394. 10.1007/s13277-015-4017-7 [DOI] [PubMed] [Google Scholar]
  85. Li J., Mo R., Zheng L. (2021a). MicroRNA-490-3p Inhibits Migration and Chemoresistance of Colorectal Cancer Cells via Targeting TNKS2. World J. Surg. Onc 19 (1), 117. 10.1186/s12957-021-02226-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Li M., Gao M., Xie X., Zhang Y., Ning J., Liu P., et al. (2019a). MicroRNA-200c Reverses Drug Resistance of Human Gastric Cancer Cells by Targeting Regulation of the NER-Ercc3/4 Pathway. Oncol. Lett. 18 (1), 145–152. 10.3892/ol.2019.10304 [DOI] [PMC free article] [PubMed] [Google Scholar]
  87. Li N., Babaei-Jadidi R., Lorenzi F., Spencer-Dene B., Clarke P., Domingo E., et al. (2019b). An FBXW7-ZEB2 axis Links EMT and Tumour Microenvironment to Promote Colorectal Cancer Stem Cells and Chemoresistance. Oncogenesis 8 (3), 13. 10.1038/s41389-019-0125-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  88. Li N., Zhang F., Li S., Zhou S. (2014). Epigenetic Silencing of MicroRNA-503 Regulates FANCA Expression in Non-small Cell Lung Cancer Cell. Biochem. Biophys. Res. Commun. 444 (4), 611–616. 10.1016/j.bbrc.2014.01.103 [DOI] [PubMed] [Google Scholar]
  89. Li W., Dong X., He C., Tan G., Li Z., Zhai B., et al. (2019c). LncRNA SNHG1 Contributes to Sorafenib Resistance by Activating the Akt Pathway and Is Positively Regulated by miR-21 in Hepatocellular Carcinoma Cells. J. Exp. Clin. Cancer Res. 38 (1), 183. 10.1186/s13046-019-1177-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  90. Li W., Wang W., Ding M., Zheng X., Ma S., Wang X. (2016b). MiR-1244 Sensitizes the Resistance of Non-small Cell Lung Cancer A549 Cell to Cisplatin. Cancer Cel Int 16, 30. 10.1186/s12935-016-0305-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Li X. X., Jin L., Sun Z. F., Gu F., Li W. L., Ma Y. J. (2013). Robo1 Expression in Non-small Cell Lung Cancer and its Brain Metastasis. Zhonghua Zhong Liu Za Zhi 35 (3), 198–201. 10.3760/cma.j.issn.0253-3766.2013.03.008 [DOI] [PubMed] [Google Scholar]
  92. Li Y., Wang L., Xu X., Sun H., Wu L. (2021b). LncRNA HLA Complex Group 11 Knockdown Alleviates Cisplatin Resistance in Gastric Cancer by Targeting the miR-144-3p/UBE2D1 Axis. Cancer Manag. Res. 13, 7543–7557. 10.2147/CMAR.S329846 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  93. Li Y., Zhang Y., Zhang S., Huang D., Li B., Liang G., et al. (2021c). circRNA circARNT2 Suppressed the Sensitivity of Hepatocellular Carcinoma Cells to Cisplatin by Targeting the miR-155-5p/PDK1 Axis. Mol. Ther. Nucleic Acids 23, 244–254. 10.1016/j.omtn.2020.08.037 [DOI] [PMC free article] [PubMed] [Google Scholar]
  94. Liang L., Jia J., Kang H., Song B. (2021). Exosomes Mediate Mir-21 to Promote Cisplatin Resistance in Lung Cancer by Regulating Pten. Acta Med. Mediterranea 37, 971–977. 10.19193/0393-6384_2021_2_148 [DOI] [Google Scholar]
  95. Lin C., Xie L., Lu Y., Hu Z., Chang J. (2018). miR-133b Reverses Cisplatin Resistance by Targeting GSTP1 in Cisplatin-Resistant Lung Cancer Cells. Int. J. Mol. Med. 41 (4), 2050–2058. 10.3892/ijmm.2018.3382 [DOI] [PMC free article] [PubMed] [Google Scholar]
  96. Lin H., Zhang L., Zhang C., Liu P. (2020). Exosomal MiR-500a-3p Promotes Cisplatin Resistance and Stemness via Negatively Regulating FBXW7 in Gastric Cancer. J. Cell Mol Med 24 (16), 8930–8941. 10.1111/jcmm.15524 [DOI] [PMC free article] [PubMed] [Google Scholar]
  97. Liu S., Li Q., Li G., Zhang Q., Zhuo L., Han X., et al. (2020). The Mechanism of m6A Methyltransferase METTL3-Mediated Autophagy in Reversing Gefitinib Resistance in NSCLC Cells by β-elemene. Cell Death Dis 11 (11), 969. 10.1038/s41419-020-03148-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  98. Liu X., Zhou X., Chen Y., Huang Y., He J., Luo H. (2020). miR-186-5p Targeting SIX1 Inhibits Cisplatin Resistance in Non-small-cell Lung Cancer Cells (NSCLCs). Neoplasma 67 (1), 147–157. 10.4149/neo_2019_190511N420 [DOI] [PubMed] [Google Scholar]
  99. Liu Y., Wang W., Li Y., Huang Y. (2020). SOX30 Confers a Tumor Suppressive Effect in Acute Myeloid Leukemia through Inactivation of Wnt/β-Catenin Signaling. Mol. Cell Probes 52, 101578. 10.1016/j.mcp.2020.101578 [DOI] [PubMed] [Google Scholar]
  100. Liu Y., Xu J., Jiang M., Ni L., Ling Y. (2020). CircRNA DONSON Contributes to Cisplatin Resistance in Gastric Cancer Cells by Regulating miR-802/BMI1 axis. Cancer Cell Int 20, 261. 10.1186/s12935-020-01358-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  101. Liu Y., Xue J., Zhong M., Wang Z., Li J., Zhu Y. (2021). Prognostic Prediction, Immune Microenvironment, and Drug Resistance Value of Collagen Type I Alpha 1 Chain: From Gastrointestinal Cancers to Pan-Cancer Analysis. Front. Mol. Biosci. 8, 692120. 10.3389/fmolb.2021.692120 [DOI] [PMC free article] [PubMed] [Google Scholar]
  102. Lu C., Shan Z., Li C., Yang L. (2017). MiR-129 Regulates Cisplatin-Resistance in Human Gastric Cancer Cells by Targeting P-Gp. Biomed. Pharmacother. 86, 450–456. 10.1016/j.biopha.2016.11.139 [DOI] [PubMed] [Google Scholar]
  103. Luo S., Shen M., Chen H., Li W., Chen C. (2020). Long Non-coding RNA TP73-AS1 A-ccelerates the P-rogression and C-isplatin R-esistance of N-on-small C-ell L-ung C-ancer by U-pregulating the E-xpression of TRIM29 via C-ompetitively T-argeting microRNA-34a-5p. Mol. Med. Rep. 22 (5), 3822–3832. 10.3892/mmr.2020.11473 [DOI] [PMC free article] [PubMed] [Google Scholar]
  104. Luo Y., Fu Y., Huang R., Gao M., Liu F., Gui R., et al. (2019). CircRNA_101505 Sensitizes Hepatocellular Carcinoma Cells to Cisplatin by Sponging miR-103 and Promotes Oxidored-nitro Domain-Containing Protein 1 Expression. Cell Death Discov 5, 121. 10.1038/s41420-019-0202-6 [DOI] [PMC free article] [PubMed] [Google Scholar]
  105. Ma Y., Li X., Cheng S., Wei W., Li Y. (2015). MicroRNA-106a Confers Cisplatin Resistance in Non-small Cell Lung Cancer A549 Cells by Targeting Adenosine Triphosphatase-Binding Cassette A1. Mol. Med. Rep. 11 (1), 625–632. 10.3892/mmr.2014.2688 [DOI] [PubMed] [Google Scholar]
  106. Meng Q. B., Peng J. J., Qu Z. W., Zhu X. M., Wen Z., Kang W. M. (2019). Eukaryotic Initiation Factor 5A2 and Human Digestive System Neoplasms. World J. Gastrointest. Oncol. 11 (6), 449–458. 10.4251/wjgo.v11.i6.449 [DOI] [PMC free article] [PubMed] [Google Scholar]
  107. Meng W., Tai Y., Zhao H., Fu B., Zhang T., Liu W., et al. (2017). Downregulation of miR-33a-5p in Hepatocellular Carcinoma: A Possible Mechanism for Chemotherapy Resistance. Med. Sci. Monit. 23, 1295–1304. 10.12659/msm.902692 [DOI] [PMC free article] [PubMed] [Google Scholar]
  108. Mi H., Wang X., Wang F., Li L., Zhu M., Wang N., et al. (2020). SNHG15 Contributes to Cisplatin Resistance in Breast Cancer through Sponging miR-381. Onco Targets Ther. 13, 657–666. 10.2147/OTT.S223321 [DOI] [PMC free article] [PubMed] [Google Scholar]
  109. Mimae T., Okada M., Hagiyama M., Miyata Y., Tsutani Y., Inoue T., et al. (2012). Upregulation of Notch2 and Six1 Is Associated with Progression of Early-Stage Lung Adenocarcinoma and a More Aggressive Phenotype at Advanced Stages. Clin. Cancer Res. 18 (4), 945–955. 10.1158/1078-0432.CCR-11-1946 [DOI] [PubMed] [Google Scholar]
  110. Momand J., Jung D., Wilczynski S., Niland J. (1998). The MDM2 Gene Amplification Database. Nucleic Acids Res. 26 (15), 3453–3459. 10.1093/nar/26.15.3453 [DOI] [PMC free article] [PubMed] [Google Scholar]
  111. Montalto F. I., De Amicis F. (2020). Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 9 (12). 10.3390/cells9122648 [DOI] [PMC free article] [PubMed] [Google Scholar]
  112. Ni Q., Zhang Y., Tao R., Li X., Zhu J. (2021). MicroRNA-95-3p Serves as a Contributor to Cisplatin Resistance in Human Gastric Cancer Cells by Targeting EMP1/PI3K/AKT Signaling. Aging (Albany NY) 13 (6), 8665–8687. 10.18632/aging.202679 [DOI] [PMC free article] [PubMed] [Google Scholar]
  113. Ning J., Jiao Y., Xie X., Deng X., Zhang Y., Yang Y., et al. (2019). miR-138-5p M-odulates the E-xpression of E-xcision R-epair C-ross-complementing P-roteins ERCC1 and ERCC4, and R-egulates the S-ensitivity of G-astric C-ancer C-ells to C-isplatin. Oncol. Rep. 41 (2), 1131–1139. 10.3892/or.2018.6907 [DOI] [PubMed] [Google Scholar]
  114. Ning M. Y., Cheng Z. L., Zhao J. (2020). MicroRNA-448 Targets SATB1 to Reverse the Cisplatin Resistance in Lung Cancer via Mediating Wnt/β-Catenin Signalling Pathway. J. Biochem. 168 (1), 41–51. 10.1093/jb/mvaa024 [DOI] [PubMed] [Google Scholar]
  115. Ohta K., Hoshino H., Wang J., Ono S., Iida Y., Hata K., et al. (2015). MicroRNA-93 Activates C-Met/PI3K/Akt Pathway Activity in Hepatocellular Carcinoma by Directly Inhibiting PTEN and CDKN1A. Oncotarget 6 (5), 3211–3224. 10.18632/oncotarget.3085 [DOI] [PMC free article] [PubMed] [Google Scholar]
  116. Pan X., Chen Y., Shen Y., Tantai J. (2019). Knockdown of TRIM65 Inhibits Autophagy and Cisplatin Resistance in A549/DDP Cells by Regulating miR-138-5p/ATG7. Cell Death Dis 10 (6), 429. 10.1038/s41419-019-1660-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  117. Panda M., Tripathi S. K., Biswal B. K. (2021). SOX9: An Emerging Driving Factor from Cancer Progression to Drug Resistance. Biochim. Biophys. Acta Rev. Cancer 1875 (2), 188517. 10.1016/j.bbcan.2021.188517 [DOI] [PubMed] [Google Scholar]
  118. Pang J., Ye L., Zhao D., Zhao D., Chen Q. (2020). Circular RNA PRMT5 Confers Cisplatin-Resistance via miR-4458/REV3L axis in Non-small-cell Lung Cancer. Cell Biol Int 44 (12), 2416–2426. 10.1002/cbin.11449 [DOI] [PubMed] [Google Scholar]
  119. Pang L., Lu J., Huang J., Xu C., Li H., Yuan G., et al. (2017). Upregulation of miR-146a Increases Cisplatin Sensitivity of the Non-small Cell Lung Cancer A549 Cell Line by Targeting JNK-2. Oncol. Lett. 14 (6), 7745–7752. 10.3892/ol.2017.7242 [DOI] [PMC free article] [PubMed] [Google Scholar]
  120. Paranjape A. N., Balaji S. A., Mandal T., Krushik E. V., Nagaraj P., Mukherjee G., et al. (2014). Bmi1 Regulates Self-Renewal and Epithelial to Mesenchymal Transition in Breast Cancer Cells through Nanog. BMC Cancer 14, 785. 10.1186/1471-2407-14-785 [DOI] [PMC free article] [PubMed] [Google Scholar]
  121. Pei K., Zhu J. J., Wang C. E., Xie Q. L., Guo J. Y. (2016). MicroRNA-185-5p Modulates Chemosensitivity of Human Non-small Cell Lung Cancer to Cisplatin via Targeting ABCC1. Eur. Rev. Med. Pharmacol. Sci. 20 (22), 4697–4704. [PubMed] [Google Scholar]
  122. Peng C., Huang K., Liu G., Li Y., Yu C. (2019). MiR-876-3p Regulates Cisplatin Resistance and Stem Cell-like Properties of Gastric Cancer Cells by Targeting TMED3. J. Gastroenterol. Hepatol. 34 (10), 1711–1719. 10.1111/jgh.14649 [DOI] [PubMed] [Google Scholar]
  123. Peng L., Sang H., Wei S., Li Y., Jin D., Zhu X., et al. (2020). circCUL2 Regulates Gastric Cancer Malignant Transformation and Cisplatin Resistance by Modulating Autophagy Activation via miR-142-3p/ROCK2. Mol. Cancer 19 (1), 156. 10.1186/s12943-020-01270-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  124. Pópulo H., Lopes J. M., Soares P. (2012). The mTOR Signalling Pathway in Human Cancer. Int. J. Mol. Sci. 13 (2), 1886–1918. 10.3390/ijms13021886 [DOI] [PMC free article] [PubMed] [Google Scholar]
  125. Qi M., Liu D., Zhang S. (2017). MicroRNA-21 Contributes to the Discrimination of Chemoresistance in Metastatic Gastric Cancer. Cancer Biomark 18 (4), 451–458. 10.3233/CBM-161732 [DOI] [PubMed] [Google Scholar]
  126. Qin X., Yu S., Zhou L., Shi M., Hu Y., Xu X., et al. (2017). Cisplatin-resistant Lung Cancer Cell-Derived Exosomes Increase Cisplatin Resistance of Recipient Cells in Exosomal miR-100-5p-dependent Manner. Int. J. Nanomedicine 12, 3721–3733. 10.2147/IJN.S131516 [DOI] [PMC free article] [PubMed] [Google Scholar]
  127. Qu W., Huang W., Yang F., Ju H., Zhu G. (2020). Long Noncoding RNA LINC00461 Mediates Cisplatin Resistance of Rectal Cancer via miR-593-5p/CCND1 axis. Biomed. Pharmacother. 124, 109740. 10.1016/j.biopha.2019.109740 [DOI] [PubMed] [Google Scholar]
  128. Rao C., Miao X., Zhao G., Zhang C., Shen H., Dong C., et al. (2019). MiR-219a-5p Enhances Cisplatin Sensitivity of Human Non-small Cell Lung Cancer by Targeting FGF9. Biomed. Pharmacother. 114, 108662. 10.1016/j.biopha.2019.108662 [DOI] [PubMed] [Google Scholar]
  129. Robey R. W., Pluchino K. M., Hall M. D., Fojo A. T., Bates S. E., Gottesman M. M. (2018). Revisiting the Role of ABC Transporters in Multidrug-Resistant Cancer. Nat. Rev. Cancer 18 (7), 452–464. 10.1038/s41568-018-0005-8 [DOI] [PMC free article] [PubMed] [Google Scholar]
  130. Ronchetti S., Zollo O., Bruscoli S., Agostini M., Bianchini R., Nocentini G., et al. (2004). GITR, a Member of the TNF Receptor Superfamily, Is Costimulatory to Mouse T Lymphocyte Subpopulations. Eur. J. Immunol. 34 (3), 613–622. 10.1002/eji.200324804 [DOI] [PubMed] [Google Scholar]
  131. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H. (1969). Platinum Compounds: a New Class of Potent Antitumour Agents. Nature 222 (5191), 385–386. 10.1038/222385a0 [DOI] [PubMed] [Google Scholar]
  132. Ru P., Steele R., Hsueh E. C., Ray R. B. (2011). Anti-miR-203 Upregulates SOCS3 Expression in Breast Cancer Cells and Enhances Cisplatin Chemosensitivity. Genes Cancer 2 (7), 720–727. 10.1177/1947601911425832 [DOI] [PMC free article] [PubMed] [Google Scholar]
  133. Sarin N., Engel F., Kalayda G. V., Mannewitz M., Cinatl J., Jr., Rothweiler F., et al. (2017). Cisplatin Resistance in Non-small Cell Lung Cancer Cells Is Associated with an Abrogation of Cisplatin-Induced G2/M Cell Cycle Arrest. PLoS One 12 (7), e0181081. 10.1371/journal.pone.0181081 [DOI] [PMC free article] [PubMed] [Google Scholar]
  134. Seidl C., Panzitt K., Bertsch A., Brcic L., Schein S., Mack M., et al. (2020). MicroRNA-182-5p Regulates Hedgehog Signaling Pathway and Chemosensitivity of Cisplatin-Resistant Lung Adenocarcinoma Cells via Targeting GLI2. Cancer Lett. 469, 266–276. 10.1016/j.canlet.2019.10.044 [DOI] [PubMed] [Google Scholar]
  135. Shah M. A., Schwartz G. K. (2001). Cell Cycle-Mediated Drug Resistance: an Emerging Concept in Cancer Therapy. Clin. Cancer Res. 7 (8), 2168–2181. [PubMed] [Google Scholar]
  136. Shen J. G., Xu S. N., Yin L. G. (2020). LncRNA NORAD/miR-202-5p Regulates the Drug Resistance of A549/DDP to Cisplatin by Targeting P-Gp. Gen. Physiol. Biophys. 39 (5), 481–489. 10.4149/gpb_2020027 [DOI] [PubMed] [Google Scholar]
  137. Shen Q., Xu Z., Xu S. (2020). Long Non-coding RNA LUCAT1 C-ontributes to C-isplatin R-esistance by R-egulating the miR-514a-3p/ULK1 axis in H-uman N-on-small C-ell L-ung C-ancer. Int. J. Oncol. 57 (4), 967–979. 10.3892/ijo.2020.5106 [DOI] [PMC free article] [PubMed] [Google Scholar]
  138. Sherr C. J., Roberts J. M. (1999). CDK Inhibitors: Positive and Negative Regulators of G1-phase Progression. Genes Dev. 13 (12), 1501–1512. 10.1101/gad.13.12.1501 [DOI] [PubMed] [Google Scholar]
  139. Shi F., Zhang L., Liu X., Wang Y. (2021). Knock-down of microRNA miR-556-5p Increases Cisplatin-Sensitivity in Non-small Cell Lung Cancer (NSCLC) via Activating NLR Family Pyrin Domain Containing 3 (NLRP3)-Mediated Pyroptotic Cell Death. Bioengineered 12 (1), 6332–6342. 10.1080/21655979.2021.1971502 [DOI] [PMC free article] [PubMed] [Google Scholar]
  140. Shi H., Li K., Feng J., Liu G., Feng Y., Zhang X. (2020). LncRNA-DANCR Interferes with miR-125b-5p/HK2 Axis to Desensitize Colon Cancer Cells to Cisplatin Vis Activating Anaerobic Glycolysis. Front. Oncol. 10, 1034. 10.3389/fonc.2020.01034 [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Shi L., Xi J., Xu X., Peng B., Zhang B. (2019). MiR-148a Suppressed Cell Invasion and Migration via Targeting WNT10b and Modulating β-catenin Signaling in Cisplatin-Resistant Colorectal Cancer Cells. Biomed. Pharmacother. 109, 902–909. 10.1016/j.biopha.2018.10.080 [DOI] [PubMed] [Google Scholar]
  142. Siddik Z. H. (2003). Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance. Oncogene 22 (47), 7265–7279. 10.1038/sj.onc.1206933 [DOI] [PubMed] [Google Scholar]
  143. Siddik Z. H. (1999). Expression of P53 in Cisplatin-Resistant Ovarian Cancer Cell Lines: Modulation with the Novel Platinum Analogue (1R, 2R-diaminocyclohexane)(trans-diacetato)(dichloro)-Platinum(IV). Clin. Cancer Res. 5, 655–663. pmid = 10100719. [PubMed] [Google Scholar]
  144. Siegel R. L., Miller K. D., Goding Sauer A., Fedewa S. A., Butterly L. F., Anderson J. C., et al. (2020). Colorectal Cancer Statistics, 2020. CA Cancer J. Clin. 70 (3), 145–164. 10.3322/caac.21601 [DOI] [PubMed] [Google Scholar]
  145. Song A. L., Zhao L., Wang Y. W., He D. Q., Li Y. M. (2019). Chemoresistance in Gastric Cancer Is Attributed to the Overexpression of Excision Repair Cross-Complementing 1 (ERCC1) Caused by microRNA-122 Dysregulation. J. Cell Physiol 234 (12), 22485–22492. 10.1002/jcp.28812 [DOI] [PubMed] [Google Scholar]
  146. Song Z., Jia G., Ma P., Cang S. (2021). Exosomal miR-4443 Promotes Cisplatin Resistance in Non-small Cell Lung Carcinoma by Regulating FSP1 m6A Modification-Mediated Ferroptosis. Life Sci. 276, 119399. 10.1016/j.lfs.2021.119399 [DOI] [PubMed] [Google Scholar]
  147. Song Z., Jia N., Li W., Zhang X. Y. (2020). LINC01572 Regulates Cisplatin Resistance in Gastric Cancer Cells by Mediating miR-497-5p. Onco Targets Ther. 13, 10877–10887. 10.2147/OTT.S267915 [DOI] [PMC free article] [PubMed] [Google Scholar]
  148. Sui C., Meng F., Li Y., Jiang Y. (2015). miR-148b Reverses Cisplatin-Resistance in Non-small Cell Cancer Cells via Negatively Regulating DNA (Cytosine-5)-methyltransferase 1(DNMT1) Expression. J. Transl Med. 13, 132. 10.1186/s12967-015-0488-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  149. Sun B., Hu N., Cong D., Chen K., Li J. (2021). MicroRNA-25-3p Promotes Cisplatin Resistance in Non-small-cell Lung Carcinoma (NSCLC) through Adjusting PTEN/PI3K/AKT Route. Bioengineered 12 (1), 3219–3228. 10.1080/21655979.2021.1939577 [DOI] [PMC free article] [PubMed] [Google Scholar]
  150. Sun G., Li Z., He Z., Wang W., Wang S., Zhang X., et al. (2020). Circular RNA MCTP2 Inhibits Cisplatin Resistance in Gastric Cancer by miR-99a-5p-Mediated Induction of MTMR3 Expression. J. Exp. Clin. Cancer Res. 39 (1), 246. 10.1186/s13046-020-01758-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  151. Sun H., Wu P., Zhang B., Wu X., Chen W. (2021). MCM3AP-AS1 Promotes Cisplatin Resistance in Gastric Cancer Cells via the miR-138/FOXC1 axis. Oncol. Lett. 21 (3), 211. 10.3892/ol.2021.12472 [DOI] [PMC free article] [PubMed] [Google Scholar]
  152. Sun J., Pan L. M., Chen L. B., Wang Y. (2017). LncRNA XIST Promotes Human Lung Adenocarcinoma Cells to Cisplatin Resistance via let-7i/BAG-1 axis. Cell Cycle 16 (21), 2100–2107. 10.1080/15384101.2017.1361071 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  153. Sun L., Yao Y., Liu B., Lin Z., Lin L., Yang M., et al. (2012). MiR-200b and miR-15b Regulate Chemotherapy-Induced Epithelial-Mesenchymal Transition in Human Tongue Cancer Cells by Targeting BMI1. Oncogene 31 (4), 432–445. 10.1038/onc.2011.263 [DOI] [PubMed] [Google Scholar]
  154. Sun T., Li K., Zhu K., Yan R., Dang C., Yuan D. (2020). SNHG6 Interacted with miR-325-3p to Regulate Cisplatin Resistance of Gastric Cancer by Targeting GITR. Onco Targets Ther. 13, 12181–12193. 10.2147/OTT.S262896 [DOI] [PMC free article] [PubMed] [Google Scholar]
  155. Sun W., Ma Y., Chen P., Wang D. (2015). MicroRNA-10a Silencing Reverses Cisplatin Resistance in the A549/cisplatin Human Lung Cancer Cell Line via the Transforming Growth Factor-β/Smad2/STAT3/STAT5 Pathway. Mol. Med. Rep. 11 (5), 3854–3859. 10.3892/mmr.2015.3181 [DOI] [PubMed] [Google Scholar]
  156. Sun W., Ping W., Tian Y., Zou W., Liu J., Zu Y. (2018). miR-202 Enhances the Anti-tumor Effect of Cisplatin on Non-small Cell Lung Cancer by Targeting the Ras/MAPK Pathway. Cell Physiol Biochem 51 (5), 2160–2171. 10.1159/000495835 [DOI] [PubMed] [Google Scholar]
  157. Sun Y., Cao Z., Shan J., Gao Y., Liu X., Ma D., et al. (2020). Hsa_circ_0020095 Promotes Oncogenesis and Cisplatin Resistance in Colon Cancer by Sponging miR-487a-3p and Modulating SOX9. Front. Cell Dev Biol 8, 604869. 10.3389/fcell.2020.604869 [DOI] [PMC free article] [PubMed] [Google Scholar]
  158. Sung H., Ferlay J., Siegel R. L., Laversanne M., Soerjomataram I., Jemal A., et al. (2021). Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71 (3), 209–249. 10.3322/caac.21660 [DOI] [PubMed] [Google Scholar]
  159. Taguchi-Atarashi N., Hamasaki M., Matsunaga K., Omori H., Ktistakis N. T., Yoshimori T., et al. (2010). Modulation of Local PtdIns3P Levels by the PI Phosphatase MTMR3 Regulates Constitutive Autophagy. Traffic 11 (4), 468–478. 10.1111/j.1600-0854.2010.01034.x [DOI] [PubMed] [Google Scholar]
  160. Tang H., Han X., Li M., Li T., Hao Y. (2019). Linc00221 Modulates Cisplatin Resistance in Non-small-cell Lung Cancer via Sponging miR-519a. Biochimie 162, 134–143. 10.1016/j.biochi.2019.04.019 [DOI] [PubMed] [Google Scholar]
  161. Tang W., Yu X., Zeng R., Chen L. (2020). LncRNA-ATB Promotes Cisplatin Resistance in Lung Adenocarcinoma Cells by Targeting the miR-200a/β-Catenin Pathway. Cancer Manag. Res. 12, 2001–2014. 10.2147/CMAR.S240695 [DOI] [PMC free article] [PubMed] [Google Scholar]
  162. Tanida S., Mizoshita T., Ozeki K., Tsukamoto H., Kamiya T., Kataoka H., et al. (2012). Mechanisms of Cisplatin-Induced Apoptosis and of Cisplatin Sensitivity: Potential of BIN1 to Act as a Potent Predictor of Cisplatin Sensitivity in Gastric Cancer Treatment. Int. J. Surg. Oncol. 2012, 862879. 10.1155/2012/862879 [DOI] [PMC free article] [PubMed] [Google Scholar]
  163. Taylor M. A., Parvani J. G., Schiemann W. P. (2010). The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-Beta in normal and Malignant Mammary Epithelial Cells. J. Mammary Gland Biol. Neoplasia 15 (2), 169–190. 10.1007/s10911-010-9181-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  164. Tian L. J., Wu Y. P., Wang D., Zhou Z. H., Xue S. B., Zhang D. Y., et al. (2019). Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) Is Associated with Cisplatin Resistance in Non-small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p. Med. Sci. Monit. 25, 8095–8104. 10.12659/MSM.916075 [DOI] [PMC free article] [PubMed] [Google Scholar]
  165. Usman R. M., Razzaq F., Akbar A., Farooqui A. A., Iftikhar A., Latif A., et al. (2021). Role and Mechanism of Autophagy-Regulating Factors in Tumorigenesis and Drug Resistance. Asia Pac. J. Clin. Oncol. 17 (3), 193–208. 10.1111/ajco.13449 [DOI] [PubMed] [Google Scholar]
  166. Velma V., Dasari S. R., Tchounwou P. B. (2016). Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells. Biomark Insights 11, 113–121. 10.4137/BMI.S39445 [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Virginie B. L., Legault L.-M., McGraw S. (2019). “Endocrine Epigenetics, Epigenetic Profiling and Biomarker Identification,” in Encyclopedia of Endocrine Diseases (Academic Press; ), 31–35. 10.1016/B978-0-12-801238-3.65830-0 [DOI] [Google Scholar]
  168. Wang C., Wang C., Qiu C., Su Z. (2020). Targeted Regulation of FoxO3a by miR-372 to Mediate Gastric Carcinoma Cell Apoptosis and DDP Drug Resistance. Cancer Biother. Radiopharm. 35 (10), 753–759. 10.1089/cbr.2019.3299 [DOI] [PubMed] [Google Scholar]
  169. Wang H., Chen J., Zhang S., Zheng X., Xie S., Mao J., et al. (2020). MiR-223 Regulates Autophagy Associated with Cisplatin Resistance by Targeting FBXW7 in Human Non-small Cell Lung Cancer. Cancer Cell Int 20 (1), 258. 10.1186/s12935-020-01284-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Wang H., Guo M., Ding D., Yang F., Chen Z. (2020). Long Non-coding RNA NNT-AS1 Contributes to Cisplatin Resistance via miR-1236-3p/ATG7 Axis in Lung Cancer Cells. Onco Targets Ther. 13, 3641–3652. 10.2147/OTT.S237576 [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., et al. (2018). MALAT1/miR-101-3p/MCL1 axis Mediates Cisplatin Resistance in Lung Cancer. Oncotarget 9 (7), 7501–7512. 10.18632/oncotarget.23483 [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Wang L., Han H., Dong L., Wang Z., Qin Y. (2021). Function of P21 and its Therapeutic Effects in Esophageal Cancer. Oncol. Lett. 21 (2), 136. 10.3892/ol.2020.12397 [DOI] [PMC free article] [PubMed] [Google Scholar]
  173. Wang L., Shang X., Feng Q. (2019). LncRNA TATDN1 Contributes to the Cisplatin Resistance of Non-small Cell Lung Cancer through TATDN1/miR-451/TRIM66 axis. Cancer Biol. Ther. 20 (3), 261–271. 10.1080/15384047.2018.1529091 [DOI] [PMC free article] [PubMed] [Google Scholar]
  174. Wang M., Zhang R., Zhang S., Xu R., Yang Q. (2019). MicroRNA-574-3p Regulates Epithelial Mesenchymal Transition and Cisplatin Resistance via Targeting ZEB1 in Human Gastric Carcinoma Cells. Gene 700, 110–119. 10.1016/j.gene.2019.03.043 [DOI] [PubMed] [Google Scholar]
  175. Wang Q., Liang D., Shen P., Yu Y., Yan Y., You W. (2021). Hsa_circ_0092276 Promotes Doxorubicin Resistance in Breast Cancer Cells by Regulating Autophagy via miR-348/ATG7 axis. Transl Oncol. 14 (8), 101045. 10.1016/j.tranon.2021.101045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  176. Wang W., Chen L., Zhu W., Huang X., Lin L., Quan Z., et al. (2021). miR-4486 Reverses Cisplatin-Resistance of colon Cancer Cells via Targeting ATG7 to Inhibiting Autophagy. Exp. Ther. Med. 22 (6), 1465. 10.3892/etm.2021.10900 [DOI] [PMC free article] [PubMed] [Google Scholar]
  177. Wang W., Yi M., Chen S., Li J., Zhang H., Xiong W., et al. (2017). NOR1 Suppresses Cancer Stem-like Cells Properties of Tumor Cells via the Inhibition of the AKT-GSK-3β-Wnt/β-Catenin-Aldh1a1 Signal Circuit. J. Cell Physiol 232 (10), 2829–2840. 10.1002/jcp.25706 [DOI] [PubMed] [Google Scholar]
  178. Wang X., Zhu J. (2018). Mir-1307 Regulates Cisplatin Resistance by Targeting Mdm4 in Breast Cancer Expressing Wild Type P53. Thorac. Cancer 9 (6), 676–683. 10.1111/1759-7714.12607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  179. Wang Z., Wang Q., Xu G., Meng N., Huang X., Jiang Z., et al. (2020). The Long Noncoding RNA CRAL Reverses Cisplatin Resistance via the miR-505/CYLD/AKT axis in Human Gastric Cancer Cells. RNA Biol. 17 (11), 1576–1589. 10.1080/15476286.2019.1709296 [DOI] [PMC free article] [PubMed] [Google Scholar]
  180. Wei X., Gao M., Ahmed Y., Gao M., Liu W., Zhang Y., et al. (2019). MicroRNA-362-5p Enhances the Cisplatin Sensitivity of Gastric Cancer Cells by Targeting Suppressor of Zeste 12 Protein. Oncol. Lett. 18 (2), 1607–1616. 10.3892/ol.2019.10496 [DOI] [PMC free article] [PubMed] [Google Scholar]
  181. Wei Y., Wei L., Li J., Ma Z., Zhang Q., Han Z., et al. (2020). SLCO4A1-AS1 Promotes Cell Growth and Induces Resistance in Lung Adenocarcinoma by Modulating miR-4701-5p/NFE2L1 axis to Activate WNT Pathway. Cancer Med. 9 (19), 7205–7217. 10.1002/cam4.3270 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  182. Weitz J., Koch M., Debus J., Höhler T., Galle P. R., Büchler M. W. (2005). Colorectal Cancer. Lancet 365 (9454), 153–165. 10.1016/S0140-6736(05)17706-X [DOI] [PubMed] [Google Scholar]
  183. Wen L., Zhang X., Zhang J., Chen S., Ma Y., Hu J., et al. (2020). Paxillin Knockdown Suppresses Metastasis and Epithelial-mesenchymal T-ransition in C-olorectal C-ancer via the ERK S-ignalling P-athway. Oncol. Rep. 44 (3), 1105–1115. 10.3892/or.2020.7687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  184. Wu C., Hu Y., Ning Y., Zhao A., Zhang G., Yan L. (2020a). Long Noncoding RNA Plasmacytoma Variant Translocation 1 Regulates Cisplatin Resistance via miR-3619-5p/TBL1XR1 Axis in Gastric Cancer. Cancer Biother. Radiopharm. 35 (10), 741–752. 10.1089/cbr.2019.3342 [DOI] [PubMed] [Google Scholar]
  185. Wu H., Zhou J., Mei S., Wu D., Mu Z., Chen B., et al. (2017). Circulating Exosomal microRNA-96 Promotes Cell Proliferation, Migration and Drug Resistance by Targeting LMO7. J. Cell Mol Med 21 (6), 1228–1236. 10.1111/jcmm.13056 [DOI] [PMC free article] [PubMed] [Google Scholar]
  186. Wu L., Wan S., Li J., Xu Y., Lou X., Sun M., et al. (2021). Expression and Prognostic Value of E2F3 Transcription Factor in Non-small Cell Lung Cancer. Oncol. Lett. 21 (5), 411. 10.3892/ol.2021.12672 [DOI] [PMC free article] [PubMed] [Google Scholar]
  187. Wu L. L., Cai W. P., Lei X., Shi K. Q., Lin X. Y., Shi L. (2019). NRAL Mediates Cisplatin Resistance in Hepatocellular Carcinoma via miR-340-5p/Nrf2 axis. J. Cell Commun Signal 13 (1), 99–112. 10.1007/s12079-018-0479-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  188. Wu S., Wang H., Pan Y., Yang X., Wu D. (2020b). miR-140-3p Enhances Cisplatin Sensitivity and Attenuates Stem Cell-like Properties through Repressing Wnt/β-Catenin Signaling in Lung Adenocarcinoma Cells. Exp. Ther. Med. 20 (2), 1664–1674. 10.3892/etm.2020.8847 [DOI] [PMC free article] [PubMed] [Google Scholar]
  189. Wu Y., Cheng K., Liang W., Wang X. (2020c). lncRNA RPPH1 Promotes Non-small Cell Lung Cancer Progression through the miR-326/WNT2B axis. Oncol. Lett. 20 (4), 105. 10.3892/ol.2020.11966 [DOI] [PMC free article] [PubMed] [Google Scholar]
  190. Xia J. T., Chen L. Z., Jian W. H., Wang K. B., Yang Y. Z., He W. L., et al. (2014). MicroRNA-362 Induces Cell Proliferation and Apoptosis Resistance in Gastric Cancer by Activation of NF-Κb Signaling. J. Transl Med. 12, 33. 10.1186/1479-5876-12-33 [DOI] [PMC free article] [PubMed] [Google Scholar]
  191. Xia Y., Lv J., Jiang T., Li B., Li Y., He Z., et al. (2021). CircFAM73A Promotes the Cancer Stem Cell-like Properties of Gastric Cancer through the miR-490-3p/HMGA2 Positive Feedback Loop and HNRNPK-Mediated β-catenin Stabilization. J. Exp. Clin. Cancer Res. 40 (1), 103. 10.1186/s13046-021-01896-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  192. Xiao F., Ouyang B., Zou J., Yang Y., Yi L., Yan H. (2020). Trim14 Promotes Autophagy and Chemotherapy Resistance of Gastric Cancer Cells by Regulating AMPK/mTOR Pathway. Drug Dev. Res. 81 (5), 544–550. 10.1002/ddr.21650 [DOI] [PubMed] [Google Scholar]
  193. Xiao H., Liu Y., Liang P., Wang B., Tan H., Zhang Y., et al. (2018). TP53TG1 Enhances Cisplatin Sensitivity of Non-small Cell Lung Cancer Cells through Regulating miR-18a/PTEN axis. Cell Biosci 8, 23. 10.1186/s13578-018-0221-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  194. Xiao X. H., He S. Y. (2020). ELF1 Activated Long Non-coding RNA CASC2 Inhibits Cisplatin Resistance of Non-small Cell Lung Cancer via the miR-18a/IRF-2 Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci. 24 (6), 3130–3142. 10.26355/eurrev_202003_20680 [DOI] [PubMed] [Google Scholar]
  195. Xie C., Subhash V. V., Datta A., Liem N., Tan S. H., Yeo M. S., et al. (2016). Melanoma Associated Antigen (MAGE)-A3 Promotes Cell Proliferation and Chemotherapeutic Drug Resistance in Gastric Cancer. Cell Oncol (Dordr) 39 (2), 175–186. 10.1007/s13402-015-0261-5 [DOI] [PubMed] [Google Scholar]
  196. Xie D., Pei Q., Li J., Wan X., Ye T. (2021). Emerging Role of E2F Family in Cancer Stem Cells. Front. Oncol. 11, 723137. 10.3389/fonc.2021.723137 [DOI] [PMC free article] [PubMed] [Google Scholar]
  197. Xie X., Huang N., Zhang Y., Wei X., Gao M., Li M., et al. (2019). MiR-192-5p Reverses Cisplatin Resistance by Targeting ERCC3 and ERCC4 in SGC7901/DDP Cells. J. Cancer 10 (4), 1039–1051. 10.7150/jca.25814 [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Xing S., Qu Y., Li C., Huang A., Tong S., Wu C., et al. (2019). Deregulation of lncRNA-AC078883.3 and microRNA-19a Is Involved in the Development of Chemoresistance to Cisplatin via Modulating Signaling Pathway of PTEN/AKT. J. Cell Physiol 234 (12), 22657–22665. 10.1002/jcp.28832 [DOI] [PubMed] [Google Scholar]
  199. Yan J., Dang Y., Liu S., Zhang Y., Zhang G. (2016). LncRNA HOTAIR Promotes Cisplatin Resistance in Gastric Cancer by Targeting miR-126 to Activate the PI3K/AKT/MRP1 Genes. Tumour Biol. 37, 16345–16355. 10.1007/s13277-016-5448-5 [DOI] [PubMed] [Google Scholar]
  200. Yang S. M., Huang C., Li X. F., Yu M. Z., He Y., Li J. (2013). miR-21 Confers Cisplatin Resistance in Gastric Cancer Cells by Regulating PTEN. Toxicology 306, 162–168. 10.1016/j.tox.2013.02.014 [DOI] [PubMed] [Google Scholar]
  201. Yang W., Xiao W., Cai Z., Jin S., Li T. (2020a). miR-1269b Drives Cisplatin Resistance of Human Non-small Cell Lung Cancer via Modulating the PTEN/PI3K/AKT Signaling Pathway. Onco Targets Ther. 13, 109–118. 10.2147/OTT.S225010 [DOI] [PMC free article] [PubMed] [Google Scholar]
  202. Yang X., Meng L., Zhong Y., Hu F., Wang L., Wang M. (2021). The Long Intergenic Noncoding RNA GAS5 Reduces Cisplatin-Resistance in Non-small Cell Lung Cancer through the miR-217/LHPP axis. Aging (Albany NY) 13 (2), 2864–2884. 10.18632/aging.202352 [DOI] [PMC free article] [PubMed] [Google Scholar]
  203. Yang X., Zhang Q., Guan B. (2020b). Circ_0110805 Knockdown Enhances Cisplatin Sensitivity and Inhibits Gastric Cancer Progression by miR-299-3p/ENDOPDI Axis. Onco Targets Ther. 13, 11445–11457. 10.2147/OTT.S279563 [DOI] [PMC free article] [PubMed] [Google Scholar]
  204. Yang Y., Zhang P., Zhao Y., Yang J., Jiang G., Fan J. (2016). Decreased MicroRNA-26a Expression Causes Cisplatin Resistance in Human Non-small Cell Lung Cancer. Cancer Biol. Ther. 17 (5), 515–525. 10.1080/15384047.2015.1095405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  205. Yeung F., Hoberg J. E., Ramsey C. S., Keller M. D., Jones D. R., Frye R. A., et al. (2004). Modulation of NF-kappaB-dependent Transcription and Cell Survival by the SIRT1 Deacetylase. EMBO J. 23 (12), 2369–2380. 10.1038/sj.emboj.7600244 [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Yi D., Xu L., Wang R., Lu X., Sang J. (2019). miR-381 Overcomes Cisplatin Resistance in Breast Cancer by Targeting MDR1. Cell Biol Int 43 (1), 12–21. 10.1002/cbin.11071 [DOI] [PubMed] [Google Scholar]
  207. Yo Y. T., Lin Y. W., Wang Y. C., Balch C., Huang R. L., Chan M. W., et al. (2012). Growth Inhibition of Ovarian Tumor-Initiating Cells by Niclosamide. Mol. Cancer Ther. 11 (8), 1703–1712. 10.1158/1535-7163.MCT-12-0002 [DOI] [PubMed] [Google Scholar]
  208. Yu S., Qin X., Chen T., Zhou L., Xu X., Feng J. (2017). MicroRNA-106b-5p Regulates Cisplatin Chemosensitivity by Targeting Polycystic Kidney Disease-2 in Non-small-cell Lung Cancer. Anticancer Drugs 28 (8), 852–860. 10.1097/CAD.0000000000000524 [DOI] [PubMed] [Google Scholar]
  209. Yun C. W., Lee S. H. (2018). The Roles of Autophagy in Cancer. Int. J. Mol. Sci. 19 (11). 10.3390/ijms19113466 [DOI] [PMC free article] [PubMed] [Google Scholar]
  210. Zachari M., Ganley I. G. (2017). The Mammalian ULK1 Complex and Autophagy Initiation. Essays Biochem. 61 (6), 585–596. 10.1042/EBC20170021 [DOI] [PMC free article] [PubMed] [Google Scholar]
  211. Zeng Z., Zhao G., Zhu H., Nie L., He L., Liu J., et al. (2020). LncRNA FOXD3-AS1 Promoted Chemo-Resistance of NSCLC Cells via Directly Acting on miR-127-3p/MDM2 axis. Cancer Cell Int 20, 350. 10.1186/s12935-020-01402-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  212. Zhan Y., Abuduwaili K., Wang X., Shen Y., Nuerlan S., Liu C. (2020). Knockdown of Long Non-coding RNA HOTAIR Suppresses Cisplatin Resistance, Cell Proliferation, Migration and Invasion of DDP-Resistant NSCLC Cells by Targeting miR-149-5p/Doublecortin-like Kinase 1 Axis. Cancer Manag. Res. 12, 7725–7737. 10.2147/CMAR.S246299 [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Zhang H., Luo Y., Xu W., Li K., Liao C. (2019). Silencing Long Intergenic Non-coding RNA 00707 Enhances Cisplatin Sensitivity in Cisplatin-Resistant Non-small-cell Lung Cancer Cells by Sponging miR-145. Oncol. Lett. 18 (6), 6261–6268. 10.3892/ol.2019.10959 [DOI] [PMC free article] [PubMed] [Google Scholar]
  214. Zhang J., He X., Ma Y., Liu Y., Shi H., Guo W., et al. (2015a). Overexpression of ROCK1 and ROCK2 Inhibits Human Laryngeal Squamous Cell Carcinoma. Int. J. Clin. Exp. Pathol. 8 (1), 244–251. [PMC free article] [PubMed] [Google Scholar]
  215. Zhang P., Sun Y., Ma L. (2015b). ZEB1: at the Crossroads of Epithelial-Mesenchymal Transition, Metastasis and Therapy Resistance. Cell Cycle 14 (4), 481–487. 10.1080/15384101.2015.1006048 [DOI] [PMC free article] [PubMed] [Google Scholar]
  216. Zhang P. F., Sheng L. L., Wang G., Tian M., Zhu L. Y., Zhang R., et al. (2016). miR-363 Promotes Proliferation and Chemo-Resistance of Human Gastric Cancer via Targeting of FBW7 Ubiquitin Ligase Expression. Oncotarget 7 (23), 35284–35292. 10.18632/oncotarget.9169 [DOI] [PMC free article] [PubMed] [Google Scholar]
  217. Zhang Q., Miao Y., Fu Q., Hu H., Chen H., Zeng A., et al. (2020a). CircRNACCDC66 Regulates Cisplatin Resistance in Gastric Cancer via the miR-618/BCL2 axis. Biochem. Biophys. Res. Commun. 526 (3), 713–720. 10.1016/j.bbrc.2020.03.156 [DOI] [PubMed] [Google Scholar]
  218. Zhang Q., Zhang B., Sun L., Yan Q., Zhang Y., Zhang Z., et al. (2018). MicroRNA-130b Targets PTEN to Induce Resistance to Cisplatin in Lung Cancer Cells by Activating Wnt/β-Catenin Pathway. Cell Biochem Funct 36 (4), 194–202. 10.1002/cbf.3331 [DOI] [PMC free article] [PubMed] [Google Scholar]
  219. Zhang W., Luo P. (2018). MicroRNA-29c Restores Cisplatin Sensitivity in Liver Cancer through Direct Inhibition of Sirtuin 1 Expression. Oncol. Lett. 16 (2), 1543–1550. 10.3892/ol.2018.8801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  220. Zhang W., Wang Z., Cai G., Huang P. (2021). Downregulation of Circ_0071589 Suppresses Cisplatin Resistance in Colorectal Cancer by Regulating the MiR-526b-3p/KLF12 Axis. Cancer Manag. Res. 13, 2717–2731. 10.2147/CMAR.S294880 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  221. Zhang X., Gu G., Li X., Zhang C. (2020b). Lidocaine Alleviates Cisplatin Resistance and Inhibits Migration of MGC-803/DDP Cells through Decreasing miR-10b. Cell Cycle 19 (19), 2530–2537. 10.1080/15384101.2020.1809914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  222. Zhao R., Zhang X., Zhang Y., Zhang Y., Yang Y., Sun Y., et al. (2020a). HOTTIP Predicts Poor Survival in Gastric Cancer Patients and Contributes to Cisplatin Resistance by Sponging miR-216a-5p. Front. Cell Dev Biol 8, 348. 10.3389/fcell.2020.00348 [DOI] [PMC free article] [PubMed] [Google Scholar]
  223. Zhao W., Li H., Yang S., Guo D., Chen J., Miao S., et al. (2019). MicroRNA-152 Suppresses Cisplatin Resistance in A549 Cells. Oncol. Lett. 18 (5), 4613–4620. 10.3892/ol.2019.10834 [DOI] [PMC free article] [PubMed] [Google Scholar]
  224. Zhao X., Li X., Zhou L., Ni J., Yan W., Ma R., et al. (2018). LncRNA HOXA11-AS Drives Cisplatin Resistance of Human LUAD Cells via Modulating miR-454-3p/Stat3. Cancer Sci. 109 (10), 3068–3079. 10.1111/cas.13764 [DOI] [PMC free article] [PubMed] [Google Scholar]
  225. Zhao Y., Zheng R., Chen J., Ning D. (2020b). CircRNA CDR1as/miR-641/HOXA9 Pathway Regulated Stemness Contributes to Cisplatin Resistance in Non-small Cell Lung Cancer (NSCLC). Cancer Cell Int 20, 289. 10.1186/s12935-020-01390-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  226. Zhao Z., Liu J., Wang C., Wang Y., Jiang Y., Guo M. (2014). MicroRNA-25 Regulates Small Cell Lung Cancer Cell Development and Cell Cycle through Cyclin E2. Int. J. Clin. Exp. Pathol. 7 (11), 7726–7734. [PMC free article] [PubMed] [Google Scholar]
  227. Zhao Z., Zhang L., Yao Q., Tao Z. (2015). miR-15b Regulates Cisplatin Resistance and Metastasis by Targeting PEBP4 in Human Lung Adenocarcinoma Cells. Cancer Gene Ther. 22 (3), 108–114. 10.1038/cgt.2014.73 [DOI] [PubMed] [Google Scholar]
  228. Zheng H., Wang J. J., Yang X. R., Yu Y. L. (2020). Upregulation of miR-34c after Silencing E2F Transcription Factor 1 Inhibits Paclitaxel Combined with Cisplatin Resistance in Gastric Cancer Cells. World J. Gastroenterol. 26 (5), 499–513. 10.3748/wjg.v26.i5.499 [DOI] [PMC free article] [PubMed] [Google Scholar]
  229. Zheng H., Zhang M., Ke X., Deng X., Li D., Wang Q., et al. (2021). LncRNA XIST/miR-137 axis Strengthens Chemo-Resistance and Glycolysis of Colorectal Cancer Cells by Hindering Transformation from PKM2 to PKM1. Cancer Biomark 30 (4), 395–406. 10.3233/CBM-201740 [DOI] [PMC free article] [PubMed] [Google Scholar]
  230. Zheng J., Li X., Cai C., Hong C., Zhang B. (2021). MicroRNA-32 and MicroRNA-548a Promote the Drug Sensitivity of Non-small Cell Lung Cancer Cells to Cisplatin by Targeting ROBO1 and Inhibiting the Activation of Wnt/β-Catenin Axis. Cancer Manag. Res. 13, 3005–3016. 10.2147/CMAR.S295003 [DOI] [PMC free article] [PubMed] [Google Scholar]
  231. Zheng P., Chen L., Yuan X., Luo Q., Liu Y., Xie G., et al. (2017). Exosomal Transfer of Tumor-Associated Macrophage-Derived miR-21 Confers Cisplatin Resistance in Gastric Cancer Cells. J. Exp. Clin. Cancer Res. 36 (1), 53. 10.1186/s13046-017-0528-y [DOI] [PMC free article] [PubMed] [Google Scholar]
  232. Zheng Z. H., You H. Y., Feng Y. J., Zhang Z. T. (2021). LncRNA KCNQ1OT1 Is a Key Factor in the Reversal Effect of Curcumin on Cisplatin Resistance in the Colorectal Cancer Cells. Mol. Cell Biochem 476 (7), 2575–2585. 10.1007/s11010-020-03856-x [DOI] [PubMed] [Google Scholar]
  233. Zhou D., Gu J., Wang Y., Wu H., Cheng W., Wang Q., et al. (2021). Long Non-coding RNA NEAT1 Transported by Extracellular Vesicles Contributes to Breast Cancer Development by Sponging microRNA-141-3p and Regulating KLF12. Cell Biosci 11 (1), 68. 10.1186/s13578-021-00556-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  234. Zhou J., Chen Q. (2019). Poor Expression of microRNA-135b Results in the Inhibition of Cisplatin Resistance and Proliferation and Induces the Apoptosis of Gastric Cancer Cells through MST1-Mediated MAPK Signaling Pathway. FASEB J. 33 (3), 3420–3436. 10.1096/fj.201800618RRR [DOI] [PMC free article] [PubMed] [Google Scholar]
  235. Zhou J. J. H. F. W. S. Y. F. L. (2020). Reversal of Drug Resistance in Gastric Cancer Cells by miR-503 and its Mechanism. Acta Med. Mediterranea 36, 1841–1848. 10.19193/0393-6384_2020_3_289 [DOI] [Google Scholar]
  236. Zhu F., Niu R., Shao X., Shao X. (2021). FGD5-AS1 P-romotes C-isplatin R-esistance of H-uman L-ung A-denocarcinoma C-ell via the miR-142-5p/PD-L1 axis. Int. J. Mol. Med. 47 (2), 523–532. 10.3892/ijmm.2020.4816 [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Zhu H., Yang J., Yang S. (2020a). MicroRNA-103a-3p Potentiates Chemoresistance to Cisplatin in Non-small Cell Lung Carcinoma by Targeting Neurofibromatosis 1. Exp. Ther. Med. 19 (3), 1797–1805. 10.3892/etm.2020.8418 [DOI] [PMC free article] [PubMed] [Google Scholar]
  238. Zhu Q. L., Li Z., Lv C. M., Wang W. (2019). MiR-187 Influences Cisplatin-Resistance of Gastric Cancer Cells through Regulating the TGF-β/Smad Signaling Pathway. Eur. Rev. Med. Pharmacol. Sci. 23 (22), 9907–9914. 10.26355/eurrev_201911_19556 [DOI] [PubMed] [Google Scholar]
  239. Zhu W., Shan X., Wang T., Shu Y., Liu P. (2010). miR-181b Modulates Multidrug Resistance by Targeting BCL2 in Human Cancer Cell Lines. Int. J. Cancer 127 (11), 2520–2529. 10.1002/ijc.25260 [DOI] [PubMed] [Google Scholar]
  240. Zhu W., Xu H., Zhu D., Zhi H., Wang T., Wang J., et al. (2012a). miR-200bc/429 Cluster Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2 and XIAP. Cancer Chemother. Pharmacol. 69 (3), 723–731. 10.1007/s00280-011-1752-3 [DOI] [PubMed] [Google Scholar]
  241. Zhu W., Zhu D., Lu S., Wang T., Wang J., Jiang B., et al. (2012b). miR-497 Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2. Med. Oncol. 29 (1), 384–391. 10.1007/s12032-010-9797-4 [DOI] [PubMed] [Google Scholar]
  242. Zhu X., Han J., Lan H., Lin Q., Wang Y., Sun X. (2020b). A Novel Circular RNA hsa_circRNA_103809/miR-377-3p/GOT1 Pathway Regulates Cisplatin-Resistance in Non-small Cell Lung Cancer (NSCLC). BMC Cancer 20 (1), 1190. 10.1186/s12885-020-07680-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  243. Zhu X., Zou S., Zhou J., Zhu H., Zhang S., Shang Z., et al. (2016). REV3L, the Catalytic Subunit of DNA Polymerase ζ, Is Involved in the Progression and Chemoresistance of Esophageal Squamous Cell Carcinoma. Oncol. Rep. 35 (3), 1664–1670. 10.3892/or.2016.4549 [DOI] [PubMed] [Google Scholar]
  244. Zhu Z., Mu Y., Qi C., Wang J., Xi G., Guo J., et al. (2015). CYP1B1 Enhances the Resistance of Epithelial Ovarian Cancer Cells to Paclitaxel In Vivo and In Vitro . Int. J. Mol. Med. 35 (2), 340–348. 10.3892/ijmm.2014.2041 [DOI] [PMC free article] [PubMed] [Google Scholar]
  245. Zou Z., Wu L., Ding H., Wang Y., Zhang Y., Chen X., et al. (2012). MicroRNA-30a Sensitizes Tumor Cells to Cis-Platinum via Suppressing Beclin 1-mediated Autophagy. J. Biol. Chem. 287 (6), 4148–4156. 10.1074/jbc.M111.307405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  246. Zuo W., Zhang W., Xu F., Zhou J., Bai W. (2019). Long Non-coding RNA LINC00485 Acts as a microRNA-195 Sponge to Regulate the Chemotherapy Sensitivity of Lung Adenocarcinoma Cells to Cisplatin by Regulating CHEK1. Cancer Cell Int 19, 240. 10.1186/s12935-019-0934-7 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Frontiers in Pharmacology are provided here courtesy of Frontiers Media SA

RESOURCES